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ABSTRACT 
Rat pancreas perfusion was performed to study the effect of bradykinin (BK) on insulin 
secretion. At the perfusate glucose concentration of 6 mM, BK (0.01 - 1 nM) increased insulin 
secretion in a concentration-dependent manner. BK (1 |iM) induced a biphasic insulin secretion, 
transiently increased glucagon secretion and decreased somatostatin secretion. In addition, BK (1 
|iM) enhanced glucose-induced insulin secretion in a glucose-dose-dependent manner. BK-induced 
insulin secretion was greatly reduced in 1 mM glucose. The level of BK-glucose (10 and 20 
mM)-induced sustained insulin secretion was higher than that of transient insulin release peak. 
Since the sustained phase is due to increased synthesis of insulin, BK may stimulate both the 
synthesis and release of insulin. HOE 140 (0.1 jiM), a BKj-receptor antagonist, abolished BK-
induced increase in insulin secretion. HOE 140 also decreased basal and glucose (10 mM)-induced 
increase in insulin secretion. Therefore, BK may play a physiological role in the regulation of 
insulin secretion via BKj-receptors. A clonal |3-cell line RINmSF was used to study the 
mechanisms underlying BK-induced rise in [Ca^^j and insulin secretion. BK increased insulin 
secretion and [Ca^^j in a concentration-dependently manner. BK (1 jiM) induced a biphasic 
[Ca^^]i rise which was characterized by a transient Ca"^ release and a sustained Ca^"^ influx phase. 
The BK-induced Ca^^ influx was triggered by Ca^^ release. The effects of BK were mediated 
through BKj-receptors which were coupled to a pertussis toxin-insensitive G protein, probably G^. 
Gq protein activated phospholipase C which promoted the formation of inositol, 1,4,5-trisphosphate 
(IP3) and diacylglycerol (DAG). IP3 released [Ca^"]; from the intracellular Ca^"^ stores, probably the 
endoplasmic reticulum, thereby triggering Ca'"^ influx via voltage-dependent Ca^"^ channels and 
increasing insulin secretion. DAG activated protein kinase C which promoted Ca^""efflux and 
inhibited Ca^"^ influx, thereby decreasing [Ca-^j and thus reducing insulin secretion. 
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Pancreatic acinar and islet cells secrete different compounds. Acinar cells secrete digestive 
juice and enzymes into the intestinal tract, while islet cells secrete hormones including insulin, 
glucagon, and somatostatin, into the blood stream, which are involved in glucose homeostasis. 
Acinar cells also secrete kallikrein, which releases kinins from the precursor kininogens or 
converts prohormones to hormone, e.g., proinsulin to insulin. The primary kinin released in the 
rat is bradykinin (BK). Although the function of BK is well understood in pain, inflammation, 
hypotension, smooth muscle contraction, the physiological role of BK in the endocrine and 
exocrine pancreas is still unknown despite the fact that kallikrein is found abundantly in the 
pancreas and kininogens are rich in the pancreas and blood circulation. In fact, the pancreas is 
one of the richest sources of kallikrein. 
Two kinins, BK and lys-BK (kallidin), increased insulin release in perfused rat and dog 
pancreata in our preliminary studies. In addition, we found that BK increased glucose-induced 
insulin release in the perfused rat pancreas (see Chapter 2). The newly synthesized BKj-receptor 
blocker, HOE 140, antagonized BK-induced insulin release and diminished glucose-induced insulin 
release in the perfused rat pancreas. HOE 140 also lowered the basal levels of insulin secretion in 
the perfused rat pancreas. Our findings support the premise that kinins and kallikrein are 
important factors involved in the regulation of insulin secretion. Patients with chronic pancreatitis 
develop diabetes mellitus, but the minor change in |3-cells can not account for the impaired insulin 
secretion. Therefore, we proposed that pancreatic kallikrein promotes the formation of BK which 
is important for maintaining adequate basal and glucose-induced insulin release. 
The islets have a and 5 cells in addition to (3 cells. The effects of BK on these cell types 
or the paracrine effects between these cells are still not well understood. Therefore, the goal of 
these studies was to investigate the stimulatory effects and the mechanisms of BK on insulin 
release, and to investigate the effects of BK on the release of glucagon and somatostatin. The 
perfused rat pancreas was used as a model to study the following phenomena: 1) BK-induced 
insulin release in the normal rat pancreas in order to understand the stimulatory effect of BK on 
insulin release from the (3 cells of islets, 2) the potentiation of glucose-induced insulin secretion by 
BK to understand the interaction between BK and glucose in insulin release on P cells, 3) the 
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inhibition of BK-induced and glucose-induced insulin secretion by the BKj-receptor blocker, HOE 
140, to determine the physiological significance of BK in the regulation of insulin release, 4). the 
glucose-dependent effect of BK on insulin release in order to investigate the importance of glucose 
for the action of BK, 5) the effects of BK on a cells and 5 cells of islets to explore the responses 
of these cells to BK in the secretion of glucagon and somatostatin. 
In order to investigate the mechanisms underlying BK-induced insulin secretion, a insulin-
secreting cell line RINmSF was used to study the mechanisms of action of BK on insulin release. 
We proposed that BK activates BKj-receptors which are coupled to a pertussis toxin-insensitive 
GTP-binding protein (G,,). The G, is coupled to an intracellular enzyme, phospholipase C (PLC). 
The activated PLC hydrolyzes phosphatidylinositol biphosphate (PIPj), resulting in the formation 
of inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). Both IP3 and DAG may contribute 
to the intracellular signals and increase the release of insulin. 
The information obtained from these studies may enhance our understanding of the role of 
BK in the regulation of insulin release. In summary, the purpose of these studies was to 
investigate the stimulatoiy effects of BK on insulin release from the perfused rat pancreas and the 
mechanisms of action of BK in rat insulinoma cells, RINmSF cells. In addition, we investigated 
the effects of BK on the release of glucagon and somatostatin, respectively, from the same samples 
collected from the pancreatic perfusion to evaluate the interactions between these different cell 
types in islets with regard to insulin release. 
Dissertation Oi^anization 
This dissertation is written in an alternative thesis format. It consists of a general 
introduction including literature review and references cited, four manuscripts, a general 
conclusion and acknowledgements. Chapter 2, "Stimulatory effect of bradykinin on insulin release 
from the perfused rat pancreas," has been published in the American Joumal of Physiology and the 
other chapters. Chapter 3, "Glucose dependency of bradykinin-induced insulin secretion in 
perfused rat pancreas," Chapter 4, "The effect of bradykinin on the secretion of insulin, glucagon 
and somatostatin from the perfused rat pancreas," and Chapter 5, "Mechanisms of bradykinin-
induced insulin secretion and a rise in cytosolic Ca^^ in a clonal P-cell line RINmSF," will be 
submitted to the American Joumal of Physiology for publication. The format used for literature 
cited in the manuscripts is according to the requirement of the submitted joumal. 
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Background and Literature Review 
Biosynthesis and Release of Islet Hormones 
In rodents, pancreatic tissue is a diffuse, almost lacy network without discrete lobular 
characteristics (Hazelwood, 1989). It contains two kinds of secretory tissues: the exocrine 
pancreas and the endocrine pancreas. The endocrine pancreas is composed of the islets of 
Langerhans which represents < 2% of the pancreas and secretes hormones such as insulin, 
glucagon, and somatostatin. The exocrine pancreas is formed by acinar cells which represents 
about 80% of the pancreas and secretes > 20 digestive emzymes. 
The islet of Langerhans consists of at least four different hormone-secreting cells. In most 
species, (3 cells which secrete insulin are generally located in the central part of the islets that 
represent 60-80% of the islet cells. They are surrounded by a cells which secrete glucagon and 
represent 15-20% of the islet cells, and somatostatin-secreting cells (5 cells) that represent 5-10% 
of the islet cells. Pancreatic polypeptide-secreting cells (k cells) that represent 15-20% of the islets 
are located in the periphery of the islets, mainly in the islets of the head of the pancreas 
(Bendayan, 1990; Miller, 1981). However, in the horse, a cells tend to localize centrally within 
the islets as small clusters (Helmstaedter et al., 1976), mainly located in the islets of the dorsal or 
splenic part of the pancreas. 
The islets of Langerhans are richly vascularized, both the islet cells and blood vessels are 
closely associated with a variety of autonomic nerves. The pancreas receives its blood supply 
from the superior and inferior pancreatic-duodenal arteries and from the pancreatic branches of the 
splenic arteiy. As the arteriole enters the islets, it forms a dense capillary network and the major 
afferent arteriole to the islet branches to supply the core of p cells first, then outward to the mantle 
in which the a cells are perfused before the 5 cells (Samols and Stagner, 1990). Thus, the cellular 
order of perfusion, p cells to a cells to 5 cells is responsible for the regulation of release of islet 
hormones. The islet capillaries are fenestrated which allow for the rapid translocation of islet 
products intothe blood stream and for maintaining glucose homeostasis. 
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Insulin 
In P cells, insulin is initially synthesized as a much larger peptide, called pre-proinsulin. 
The pre-proinsulin molecule consists of an insulin molecule which has the A (21 amino acids) and 
B (30 amino acids) chains, a connecting peptide (31-35 amino acid residues, depending on species) 
and a leading sequence of 23 amino acid residues (24 in rats) in the N-terminal of B chain. As 
pre-proinsulin enters the rough endoplasmic reticulum, the leading sequence is cleaved by 
microsomal enzymes, and forms proinsulin, an intermediate in the formation of active insulin 
(Steiner et al., 1967). During the translocation process within the microvesicles, proinsulin is 
cleaved by proteolytic enzymes including kallikrein to release the connecting peptide, insulin, and 
the four basic residues. Some of the cleavage occurs during Golgi apparatus processing of the 
granules-to-be, and a small fraction occurs after the formation of secretory granules. Proinsulin 
has only about 10% of the activity of insulin. 
Most of the insulin, including the newly synthesized proinsulin, is stored in secretory 
granules and is released only after stimulation by secretagogues. This is called the classic or 
regulated pathway. However, some of the insulin is directly secreted from the Golgi apparatus to 
the plasma membrane after being synthesized, which allows the hormones to leak out. This is 
called the constitutive pathway (Rhodes and Halban, 1987). Insulin secretagogues promote the 
unidirectional movement of insulin granules away from the Golgi apparatus toward the cell 
membrane. The intracellular microtubular-microfilamentous system is involved in the transport of 
secretory granules toward the plasma membrane. In addition, subcellular components including 
tubulin, actin, and cytosolic Ca^"^ are involved in the exocytosis of insulin granules. When P cells 
are stimulated with glucose, it produces oscillations of [Ca^^]j and is followed by the 
synchronization of these signals which evoke a pulsatile release of insulin (Hellman et al., 1994). 
The rat insulin molecular structure is similar to that of human insulin which is shown in 
Fig. 1 as the shaded polypeptide A and B chains. The A and B chains are connected by two 
interchain disulfide bonds which occur at positions A7-B7 and Ajo-B,,. In addition, an intrachain 
disulfide bond occurs at positions Ag-A,, (Hazelwood, 1989). In rats, there are two insulin-
producing genes, thus they produce two variants of insulin, rat insulin I and II, which are different 
at B29 (Gross et al., 1988). Rat insulin I and II are synthesized in a ratio of as approxmately 60 : 
40 (Gishizky and Grodsky, 1987) 
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C-PEPTIDE 
A-CHAlN 
B-CHAIN 
Fig. 1. Human proinsuiin structure. Insulin is shown as the shaded polypeptide A and B chains. 
The rat insulin differs from the human insulin by having a lysine and serine instead of a arginine 
and threonine at positions B3 and B30, respectively (Bunzli et al., 1972). 
Glucagon 
Glucagon is a straight-chain polypeptide with 29 amino acid residues without any disulfide 
bonds. It is synthesized in a cells as a larger protein called pre-proglucagon with 179 amino acid 
residues. The biosynthesis of glucagon in a cells is similar to that of insulin in P cells. It 
involves translocation of new synthesized pre-proglucagon from polysomes into endoplasmic 
reticulum, cleavage of leader peptide and formation of proglucagon before the encapsulation within 
microvesicles, transportation of microvesicies to Golgi apparatus, formation of secretory glucagon 
granules, and exocytosis by stimulation (Noe et al., 1981). The amino acid sequence of rat and 
human glucagon are identical. 
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Somatostatin 
Somatostatin secreted by pancreatic 5 cells is identical in structure to that found in other 
parts of the body. The pancreas contains the highest concentration of tissue somatostatin. The 
biosynthesis of somatostatin is similar to that of insulin in P cells and glucagon in a cells. The rat 
prosomatostatin has 121-125 amino acid residues. When the prosomatostatin is packaged in the 
Golgi apparatus, most of the prosomatostatin is cleaved into somatostatin with 28 amino acid and 
then it is cleaved again into somatostatin with 14 amino acid residues (Hazelwood, 1989). 
Interactions Between Islet Hormones 
The intra-islet blood flow is from p cells to a cells and from a cells to 5 cells. 5 Cells 
are located in the islet mantle interspaced among a cells, and the endocrine pancreatic hormones 
are released into the circulation. Thus insulin regulates the release of glucagon, and then both 
insulin and glucagon regulate the release of somatostatin (Samols and Stagner, 1990). However, 
the islet hormones are actually released into the extracellular space which may produce a paracrine 
effect on the surrounding cells through local diffusion. 
Insulin inhibits the release of glucagon, but stimulates the release of somatostatin 
(Greenbaum et al., 1991). In addition, insulin promotes glucose transport which inhibits the 
release of glucagon (Greenbaum et al., 1991). Insulin secretion is inhibited by the secreted insulin 
through a local feedback mechanism (Ammon et al., 1991). Glucagon increases the release of 
insulin and somatostatin, but both insulin and somatostatin inhibit the release of glucagon (linger 
and Orci, 1977). 
Recently, somatostatin receptors were found in P cells (Thermos et al., 1990). 
Somatostatin inhibits the release of insulin and glucagon from p and a cells, respectively (Hoyer 
et al., 1994), enhances insulin sensitivity, and increases utilization of glucose (Moller et al., 1995). 
These actions may be mediated by a paracrine effect (Unger and Orci, 1977). 
Effect of Islet Hormones on Exocrine Pancreas 
Due to the islet-acinar portal system and the dispersion of islets in the exocrine pancreas 
there may be interaction between these two tissues. In addition, islet hormone (insulin and 
somatostatin) receptors exist on the plasma membrane of pancreatic acinar cells (Bendayan, 1990) 
and the periacinal islet hormone concentrations are at least 20-fold higher in concentration than 
those in the systemic circulation (Bendayan, 1993). Thus, pancreatic islet hormones may regulate 
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the secretion of the exocrine pancreas (Nakagawa et al., 1995; Hasegawa et al., 1993). 
Insulin directly regulates the fiinction of exocrine pancreas including the release of 
zymogen, glucose transport, and protein synthesis (Williams and Goldfine, 1985). In addition, 
insulin increases secretin-induced pancreatic juice release, but does not affect the release of 
protein. However, both glucagon and somatostatin inhibit secretin-induced pancreatic juice and 
protein secretion (Hasegawa et al., 1993). 
RINmSF Insulinoma Cells 
Establishment of RIN-m Cell Line 
Because the pancreatic islet contain other types of cells in addition to insulin-secreting p 
cells, it is not suitable for studying the mechanisms of action of agents affecting insulin release. 
In addition, it is difficult to study the subcellular and molecular components from the small 
amounts of islet p cells. Thus, the RIN-m cell line was established for these studies. 
The RIN-m cell line was developed from a transplantable insulinoma in inbred albino rats 
of the New England Deaconess Hospital (NEDH) strain by exposing the pancreas to x-ray 
irradiation. The original tumor, about 1 cm in diameter, came from a male parabiont. 
Subsequently, the small fragments were transplanted and continuously grew in NEDH rats for 9 
transplantations. After 7 transplantations, the period for the tumor growth to 0.5-1.5 cm was 
decreased from 5-8 months in the first transplantation to 2-5 months. The tumor in male rats is 
larger than in female rats (Chick et al., 1977). 
The cells kept in inbred rats are called RIN-r, whereas, the cells maintained in athymic 
nude mice are called RIN-m. After RIN-m was transplanted in athymic nude mice for four series, 
five cell clones designated 1 to 5 were selected. Thus, the cell line, RINmSF which secretes high 
concentrations of insulin, is one of the clones of RIN-m (Gazdar et al., 1980). 
The cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum. 
Usually, the cell population doubling time is 60-80 hours. The RINmSF cells are epithelioid and 
tumorigenic and have a hypodiploid chromosome number. The cells grow faster at later passages 
than at earlier passages. At earlier passages, RIN cells have neuron-like processes, but they 
change to round-shaped cells after long-term culture (Willingham, 1976). 
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Functional Characterizations 
RIN cells secrete both insulin and somatostatin, but they have a relatively high capacity to 
secrete insulin when they are maintained in the RPMI-1640 medium (Gazdar et al., 1980; 
Bhathena et al., 1984). The amount of insulin secretion varies depending on the duration and 
culture medium. Furthermore, the variation in insulin production is related to the stability of 
mRNA which subsequently affects the synthesis of insulin (Muschel et al., 1986). 
RINm5F cells contain 0.19 pg insulin/cell which represents approxmately 1% of the 
insulin content of normal (3 cells. When RINmSF cells are cultured with 2.8 mM glucose for 60 
minutes, they releases 7-12% of their cellular content of insulin. By increasing glucose 
concentrations from 2.8 to 16.7 mM, RINmSF cells increase the utilization of glucose, but do not 
increase insulin release even when glucose concentration is increased to 33.4 mM (Praz et al., 
1983). Thus, they have a relatively high basal insulin secretion but a modest, monophasic increase 
in insulin secretion in response to glucose (Leclercq-Meyer et al., 1988). 
Although RIN cells secrete somatostatin, the rate of somatostatin secretion is stable and 
maintained at the range from 3.15 to 8.70 ng/million cells/24 hrs. The simultaneous secretion of 
somatostatin may influence insulin secretion during culture (Basabe et al., 1977). 
Biochemical Characterizations 
Insulin secretion from RINmSF cells is increased by Ca^^, K"", tolbutamide, theophylline, 
glucagon (Bhathena et al., 1984), leucine, and dibutyryl cAMP, but not by glucose (Sopwith et al., 
1981). Insulin secretion is inhibited by oxidative phosphorylation inhibitors (cyanide and 2,4-
dinitrophenol), Ca""^ flux blockers (EGTA, verapamil, and Mg"^, calmodulin antagonist 
(trifluoperazine), microtubule inhibitors (vinblastine and colchicine) as well as epinephrine and 
somatostatin. Thus, the exocytotic mechanisms of insulin secretion in these insulinoma cells are 
similar to those of normal islet cells (Sopwith et al., 1981). The difference between RINmSF cells 
and normal islet p cells is that RINmSF cells do not response to glucose or arginine (Bhathena et 
al., 1984). 
In normal pancreatic (3 cells, glucokinase which contributes about 75% of the total glucose 
phosphorylation capacity regulates the metabolic flux rate through the glycolytic chain and 
generates the signal for glucose-induced insulin release (Lenzen et al., 1987a). The activity of 
glucokinase is decreased in RINmSF cells; it appears to result from a loss of the ability of insulin 
to stimulate this enzyme. Thus, RINmSF cells show a single low-Km (hexokinase-like activity) 
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component of glucose utilization and lack the ability to stimulate insulin release in response to 
glucose (Lenzen et al., 1987b). However, in normal islet P cells, glucose stimulates insulin release 
with the high-Km (glucokinase-like activity) component of glucose utilization ( Halban et al., 
1983). 
RINmSF cells also express a high level of amine precursor uptake and decarboxylation, 
(APUD) cell enzyme, L-dopa-decarboxylase and L-amino acid decarboxylase (Oie et al., 1983). 
Thus, they resemble the APUD cells series in biochemical, fiinctional and morphological features 
(Pearse, 1980), 
Kallikrein-Kinin System 
Kallikrein 
Kailikrein was first found in the extracts of porcine, bovine, and human pancreata. Thus, it 
was named kallikrein after an old greek synonym for that organ, kallikreas (Prey et al., 1950). 
Kallikreins are serine proteases which enzymatically release smooth muscle-contracting substances, 
kinins, from endogenous substrates, kininogens (Miiller-Ester, 1989). Kallikreins are involved in 
the processing of prohormones into biological active hormones (Seidah et al., 1988; Bothwell et 
al., 1979), such as the formation of insulin from proinsulin (Ole-Moiyoi et al., 1979) and renin 
from prorenin (Sealey et al., 1978). 
The kallikrein-kinin system can be divided into the plasma kallikrein-kinin system and the 
tissue kallikrein-kinin system (Fiedler, 1979). At the molecular level, tissue and plasma kallikreins 
are two completely different proteins. They differ in their molecular weights, substrate 
kininogens, types of kinin released, and physiological ftinctions (Bhoola, 1992). Recently, another 
kininogenase, T-kininogenase (Bedi et al., 1983; Damas and Adam, 1985) which releases T-kinin 
from T-kininogen, was found to occur only in the rat (Okamato and Greenbaum, 1983). 
Plasma Kallikrein 
Chemistry and Synthesis 
Plasma kallikrein molecule has 619 amino acids. After cleaving the single peptide bond 
between Arg^^' and Ile^'^, it forms a two-chain (heavy and light chain) protease which is held 
together by a disulfide bond with an enzyme catalytic site in the light chain (35 or 38 KDa) 
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(Bhoola et al, 1992) and a Hageman factor binding region in the heavy chain (Veloso et al., 1987). 
All of the kallikreins are synthesized in a precursor form called prekallikrein. Plasma 
prekallikrein is synthesized in the liver from a single gene expression and circulates in the plasma 
(Seidah et al., 1989). It is a single-chain glycoprotein and exists in two forms with molecular 
weights of 85 and 88 Kda, respectively (Mandle and Kaplan, 1977). Plasma prekallikrein can be 
activated by the Hageman-factor or by negative charged surfaces like collagen and endotoxin 
(Bonner et al., 1986) and is involved in the blood clotting cascade (Bhoola et al., 1992). 
Functions 
Kallikreins liberate kinins from kininogens. In mammals, there are three types of 
kininogens: 1) a high molecular weight kininogen (HMK) found in the blood, 2) low molecular 
weight kininogen (LMK) found in the blood and in various tissues (Jacobsen, 1966), and 3) T-
kininogen which was discovered recently and found only in rats (Okamoto and Greenbaum, 1983). 
T-kininogen is markedly increased as an acute phase protein in cases of trauma, surgery, and toxin 
exposure (Mindroiu et al., 1987). It inactivates cysteine proteases involved in inflammation 
(Potempa et al., 1988). 
The plasma kallikrein releases BK from HMK by hydrolysis of the Lys-Arg and Arg-Ser 
bond to form a nonapeptide with arginine residues on both N- and C- terminals. LMK is not a 
good substrate for plasma kallikrein, but in the presence of neutrophil elastase which acts on LMK 
and forms a kinin-containing fragment (26 amino acid residues), plasma kallikrein can release BK 
from the fragment (Sato and Nagasawa, 1988). 
Tissue Kallikrein 
Chemistry and Synthesis 
Tissue kallikreins have been purified and characterized from the pancreas of pigs 
(Kutzbach and Schmidt-Kastner, 1972), rodents, and dogs (Hojima et al., 1975). They also exist 
in the rat aorta (Oza et al., 1990), rat mesenteric and tail arteries (Nolly and Lama, 1982), and 
other tissues. They are acidic glycoproteins with pi values ranging from 3.5-4.4 and have a 
molecular weights ranging from 24 to 45 KDa (Fiedler, 1979). The catalytic reaction is similar to 
that of trypsin and the other serine proteases (Fiedler, 1979; Pisano, 1975). The half-life of tissue 
kallikrein is 16 minutes in normal animals (Ward and Mills, 1974). 
Tissue (glandular) prekallikreins are synthesized by different genes in different tissues 
(Mason et al., 1983; Qin et al., 1991). They are similar but not identical enzymes in different 
organs of one species, such as in the rat. The tissue kallikrein multigene family contains 20 
closely related genes and they are synthesized in different expression patterns (Shai et al., 1989). 
Recently, the mRNA of tissue kallikrein has been isolated in the pancreas (Swift et al., 1982), 
kidney (Inoue et al., 1989), and other tissues of the rat. Thus, tissue kallikrein is synthesized in the 
rat pancreas including acinar cells (0rstavik, 1981; 0rstavik et al., 1976) and islet p cells (Pinkus 
et al., 1983),. The concentration of tissue kallikrein is influenced by pathological inflammation. 
For example, such as the concentration of tissue kallikrein in the blood was increased in acute 
pancreatitis with shock induced by taurocholic acid in piglets (Kortmann, 1984). 
Functions 
In most species, tissue kallikrein (except the rat and mouse enzyme) forms a decapeptide 
kallidin (Lys-BK) fi-om LMK by cleavage of the Met-Lys bond at the N-terminus and Arg-Ser 
bond at the C-terminus (Iwanaga et al., 1977). However, tissue kallikrein is considered to release 
kinins from both HMK and LMK (Iwanaga et al., 1977; Girolami et al., 1986). 
In rats, the formation of BK is catalyzed by tissue kallikrein, because in the rat HMK, at 
the N-terminal sequence of the BK, an Arg-Arg sequence replaces the Met-Lys-Arg sequence in 
other species (Kate et al., 1985). Therefore, both kallidin and BK are found in human and other 
species, whereas BK, but not kallidin is found in rats. However, the bioactivities of kallidin and 
BK are similar (Bhoola et al., 1992). The lys-BK is rapidly converted into BK through the 
removal of the N-terminal lysine by an unspecific aminopeptidase (Bhoola et al., 1992). 
Kininogens 
Chemistry 
The molecular structures and functional domains of HMK and LMK have been determined 
by Miiller-Esterl and coworkers in 1986 (Fig. 2). The kininogens are single-chain glycoproteins. 
They consist of a heavy chain including domains 1, 2, and 3 in the N-terminal, a light chain which 
contains domains 5 and 6 in the C-terminal, and the kinin moiety (domain 4) that is located 
between the two chains (Kellermann et al., 1987). HMK has 626 amino acids which forms 6 
domains with molecular weights ranging from 88 to 120 KDa (Kato et al., 1976; Yamamoto, 
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1987), and LMK has 409 amino acids which only consists of 5 domains with the molecular 
weight ranging from 50 to 68 KDa (Kato et al, 1976). The heavy chains of all three kininogens 
have a similar basic structure (Bhoola et al., 1992; Higashiyama et al, 1986). In contrast, light 
chains distal to the kinin moiety have different lengths and different molecular weights, 45 to 58 
KDa in HMK and 4 to 5 KDa in LMK, respectively (Kitamura et al., 1983; Takagaki et al., 1985), 
(a) H-Klninogen (b) L-Kininogen 
Hsavy Chains ; 01432 & 03'inhlbilor domains tor cysiein« proteinases 
04 • Kirw domain 
H-kininogen . 05 » Mstldina rich domain 
Light chain * D6 = bindng site for plasma pre-kalkrein and clotting /actor XI 
L-kininogen 
Light chain 05 = unknown (urKtlon 
Fig. 2. Structure of human kininogens, indicating the domains of high molecular weight kininogen 
(a) and low molecular weight kininogen (b). 0, potential disulphide loop; t, carbohydrate 
attachment site; ©, histidine-rich region; X, cleavage site for kallkrein. From Muller-Esterl et al. 
(1986) 
Synthesis 
Kininogens are primarily synthesized as prekininogens by hepatocytes, and subsequently 
modified through posttranslational glycosylation and stored prior to secretion into the circulation 
(Kitamura et al., 1983; Takagaki et al, 1985). However, T-kininogen is released immediately after 
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it is synthesized (Baussant et al, 1988; Bhoola et al., 1992). The synthesis of kininogens also 
occurs in the cortex and medulla of the kidney (Iwai et al., 1988) and endothelial cells (Schmaier 
et al.,1988), because the present and expression of kininogen mRNA have been demonstrated in 
these tissues. After synthesis, HMK is transported to the plasma membrane (Schmaier et al, 1983) 
and attaches there by the domains 3 and 5 of the heavy chain and light chains, respectively 
(Schmaier et al., 1987). The plasma concentration of total HMK is 55 fig/ml (Bhoola et al., 
1992). 
Functions 
There are specific receptors for HMK on the plasma membrane of platelets (Gustafson et 
al., 1986), human endothelial cells (Schmaier et al., 1988), and neutrophils (Gustafson et al., 
1989). HMK can bind to the surface receptors of human umbilical endothelial cells by its heavy 
and light chains, which provides the source of BK , inhibits cysteine proteinases (Higashiyama et 
al., 1986) and has procoagulant properties ( Nishikawa et al., 1992; Reddigari et al., 1993). 
The binding of HMK to the platelet membrane may provide a surface to regulate the 
contact phase activation of platelets (Gustafson et al., 1986), since HMK is the major inhibitor for 
the thrombin-induced activation of platelets (Puri et al., 1987) by interfering with the binding of 
fibrinogen to specific membrane receptors (C3R) of activated platelets and neutrophils (Gustafson 
etal., 1989). 
The heavy chains of all three kininogens have a similar ability to inhibit SH-proteinases 
such as calpains and papain (Higashiyama et al., 1986). The domain 5 of the light chain in HMK 
which is rich in histidine, proline, and lysine can bind to the negative charge on the damaged 
surfaces of endothelial cells and enhance the blood clotting cascade (Kaplan, 1978). The binding 
of domain 5 to specific receptors through a bridge promotes the internalization of circulating 
kininogen into endothelial cells (Bhoola et al., 1992). Domain 6 possesses the binding capacity to 
plasma prekallikrein or clotting factor XI (Tait and Fijikawa,1987). Domain 6 also enhances the 
binding of plasma prekallikrein to the plasma membrane of neutrophils. The light chains of LMK 
and T-kininogen are formed by only one domain and their function is still unknown. 
1 4  
Kinins 
Chemistry 
The autacoid bradykinin (BK) is a potent bioactive peptide which is released from 
kininogens by the enzymatic action of kallikreins. The amino acid sequence of BK is H2N-Arg-
Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH with arginine on both N- and C- terminals. 
There are many endogenous BK analogues, such as Lys-BK, Met-Lys-BK, Gly-Arg-Met-
Lys-BK. Met-Lys-BK is released by another two enzymes: pepsin and uropepsin (Hial et al., 
1976). The relative potency of these BK analogues on smooth muscle (guinea pig ileum) is in the 
following ranking order: BK > Lys-BK > Met-Lys-BK > Gly-Arg-Met-Lys-BK, but the activity on 
vascular permeability and blood pressure is in inverse order (Reiss et al., 1971). 
There are a large amount of kinins in tissues and up to 13 |.ig/ml of kinins can be 
produced with trypsin in human plasma (Rocha e Silva, 1960). The range of plasma BK 
concentrations is from undetectable to 3 ng/ml in normal animals (Talamo et al., 1969). The 
formation of BK is increased in endotoxic shock (Kimball et al., 1972), but decreased in alcoholic 
cirrhosis (Wong et al., 1972). 
Another two mammalian kinins, Ile-Ser-BK (T-kinin) and Met-Ile-Ser-BK, are found only 
in the plasma and pouch fluid of rats (Okamoto and Greenbaum, 1983). T-kinin is released from 
T-kininogen by T-kininogenase (Bedi et al., 1983; Damas and Adam, 1985). T-kinin can be 
converted into BK by aminopeptidase M in the rat kidney (Vieira et al., 1994). The plasma 
concentration of T-kinin and T-kininogen are too low to be detected (Campell et al., 1993). 
Breakdown 
After kinins are produced, they are rapidly degraded within a few seconds by kininases 
which are abundant in body fluids. The half-lives of kinins are estimated to be less than 30 
seconds in the blood, they thus act as local hormones or autacoids (McCarthy et al., 1965). 
There are at least three peptidases called kininases: kininase I (KI), kininase II (KII), and 
endopeptidase. The kininase I family, including plasma kininase I-carboxypeptidase N (KI-CPN) 
(Erdos, 1979) and the cell membrane enzyme kininase I-carboxypeptidase M (KI-CPM) (Skidgel et 
al., 1984), acts on the C-terminus of kinin molecules by removing the terminal Arg' and produces 
a BK,-receptor agonist, des[Arg']-BK or des[Arg']lys-BK (Bhoola et al., 1992). The released 
arginine may provide the substrate for the formation of nitric oxide by nitric oxide synthase within 
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the endothelial cells (Erd5s, 1990; Moncada et al., 1988). 
The kininase II family, including kininase Il-angiotensin I-converting enzyme (KIl-ACE) 
(Erdos, 1979) and kininase Il-neutral endopeptidase (KII-NEP) (Almenoff and Orlowski, 1983), 
cleaves the Pro'-Phe® bond and releases a dipeptide, Phe^-Arg". Then KII-ACE liberates Se^-Pro' 
by cleaving the Phe^-Sei^ bond from the kinin molecules (Erdos, 1979). The other kininases 
include prolidase (aminopeptidase P) which cleaves the Arg'-pro^ bond of BK, and another two 
endopeptidases (kininases A and B). 
Circulating BK is primarily degraded in the lung (Vane, 1969; Ferreira and Vane, 1967). 
The plasma concentrations of kinin are primarily controlled by KJ-CPN, but in the pulmonary 
vascular bed the kinin concentrations are controlled by KII-ACE in rat plasma (Ishida et al., 1989). 
Functions 
Kinins are potent vasoactive peptides that influence a number of biological processes 
including the regulation of blood pressure (Nwator and Whalley; 1989; Pan et al., 1993), 
inflammation and pain (Carter et al., 1974; Whalley et al., 1987), contraction of smooth muscle 
(Collier et al., 1962; Bhoola et al., 1992), neurotransmission (Higashida, 1988; Liona et al., 1991), 
hypoglycemia (Wicklmayr and Dietze, 1977), cell proliferation (Goldstein et al., 1984; Marceau 
and Trembley, 1986), transportation of electrolytes (Brock et al., 1988; Sharp and Debnam, 1992) 
and other cellular functions. All of these studies suggest that kinins are involved in numerous 
normal and patho-physiological functions (Pisano and Austin, 1974). 
Regulation of Blood Pressure 
The vasodilatory effects of kinins have been increasingly studied. Kinins may be useful 
for treating clinic cardiac, cerebral, or renal ischemia by reducing or limiting the size of the 
infarct, preventing cardiovascular contraction, improving blood perfusion and the function of 
organs (Linz et al., 1986, 1990). 
The coronary infusion of BK reduces reperfusion injury and prevents arrhythmias in 
isolated ischemic hearts (Linz et al., 1986;1990). This protective effect may be related to the 
reduction in the release of cardiac norepinephrine (Ribuot et al., 1994). In addition, intracoronary 
infusion of BK transiently inhibits myocardial contractions, and the effect in contractile 
performance can be reduced by an ATP-sensitive K^ channel blocker, glibenclamide, suggesting 
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that it acts through the opening of channels (Fort and Lewis, 1993). In the kidney of diabetic 
patients and streptozotocin-induced diabetic rats, kinins mediate the renal vasodilation, increased 
glomerular filtration rate and renal blood flow (Jaffa et ai., 1995). 
The hypotensive response and increased local blood flow are mediated through the BK,-
receptors in the aorta of rabbits (Nwator and Whalley, 1989). However, the exercise pressor reflex 
is mediated through the BKj-receptors located on the nerve endings of the muscle afferent nerves 
in cats (Pan et al., 1993). The effects of BK on vascular endothelial cells depend on the presence 
of endothelium-relaxing factors, nitric oxide (NO), and prostaglandin E2 (Furchgott, 1981). 
Inflammation and Pain 
Kinins are potent pain-producing substances (Whalley et al., 1987) and there are many 
studies about the role of kinins in inflammation, tissue damage, antigen-antibody reactions, and 
anaphylactic and septic shock. Recently, tissue kallikrein was found in neutrophils (Figueroa and 
Bhoola, 1989) and the attachment of LMK, HMK, and plasma prekallikrein to the surface of the 
neutrophil plasma membrane provides evidence that kinins are produced and are involved in the 
inflammatory processes (Figueroa, 1990). Kinins are the primary components involved in 
inflammation. Kinins produce pain by stimulating nociceptive sensory C-fiber terminal (Steranka 
et al., 1988). Kinins promote the release of substance P, followed by an increase of vascular 
permeability, leakage of serum proteins and fluid from the capillaries, and local vasodilation. 
Tissue edema and flare are then observed (Reis et al., 1971; Carter et al., 1974). Subsequently, 
monocytes release cytokines which attract leukocytes to the injection site (Bhoola et al., 1992) and 
inflammatory processes are initiated. 
Kinins are produced in airway secretions in some pulmonary diseases and inflammation, 
such as allergic or viral rhinitis, and asthma. The release of kinins activates the plasma and tissue 
kallikrein systems, increases vascular permeability, and stimulates sensory nerves to produce 
symptoms of nasal obstruction, rhinorrhea, and airway irritation (Proud, 1994). 
Contraction of Smooth Muscle 
In most species, kinins initiate a biphasic response on isolated airway smooth muscle. 
Kinins relax the airway smooth muscle at low concentrations (Bhoola et al., 1989), but produce 
contractions at higher concentrations (Collier et al., 1962). The mechanisms of BK-induced 
bronchocontraction may involve prostanoids, thromboxanes, substance P, and neuropeptides, the 
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stimulation of bronchial C-fiber, and direct stimulation (Bhoola et al., 1992). 
Kinins also initiate the contraction of intestine and uterus via BKj-receptors (Figueiredo et 
al., 1990; Bhoola et al., 1992). The contraction of the small intestine is partly mediated through 
the direct action of BK and partly mediated by the stimulatory effect of acetylcholine released 
from the efferent cholinergic nerves (Palov and Ovsiannikov, 1988). However, BK relaxes rat 
duodenum which is mediated by BKj-receptors (Bhoola, 1961). 
Neurotransmission 
The cellular actions of kinins are modified by their ability to stimulate the release of many 
second signal mediators, eg., platelet activating factors and prostaglandins (Cahill et al., 1988), 
endothelium derived relaxing factor (EDRF) (Liao and Homey, 1992), leukotrienes, substance P 
(White and Zimmermann, 1988), acetylcholine (Higashida, 1988), catecholamines (Liona et al., 
1991), and cytokines (interleukin-I,IL-I; Tumor necrosis factor,TNF) (Tiffany and Burch, 1989). 
Kinins also stimulate the secretion of other hormones, eg., renin from the kidney 
(Beierwaltes et al., 1985), and vasopressin from the neurohypophysis (Baertschi et al., 1981). BK 
stimulates the release of interleukin-1 which enhances the receptor-mediated release of 
prostaglandin E2 by more than 10 times through the activation of phospholipase Aj and 
cyclooxygenase (Burch et al., 1988). 
Modulation of Glucose Metabolism 
Kinins decrease the blood glucose concentration in type II diabetic humans and dogs 
(Bhoola et al., 1992; Wicklmayr and Dietze, 1977). The infrision of BK increases the blood 
glucose uptake of the skeletal muscle by 2-fold without increasing the formation of lactate in 
patients with postoperative stress syndrome (Jauch et al., 1986, 1988). 
BK also stimulates the absorption and metabolism of glucose in rat jejunum (Kellett and 
Barker, 1989). The BK-induced increase in absorption of glucose is mediated by Na^-dependent 
glucose uptake at the brush-border and carrier-mediated transport across the basolateral membrane 
(Sharp and Debnam, 1992). 
Other Functions 
BK increases the transport of electrolytes by stimulating the Na'^-K^-Cl" cotransporter in 
cultured endothelial cells (Brock et al., 1988). BK promotes protein synthesis and cell division 
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(Goldstein and Wall, 1984; Marceau and Tremblay, 1986). In addition, kinins stimulate the 
proliferation and enhance the metastases of tumor cells by increasing vascular permeability 
(Roberts, 1989; Bhoola et al., 1992). 
Receptor Classification 
BK receptors are classified according to the relative potency of kinin agonists on isolated 
smooth muscle preparations (Bhoola et al., 1992) (Table 1). So far, at least two types of kinin 
receptors, BK,- and BK^-receptors, have been characterized (Regoli et al., 1990). These receptors 
are encoded by distinct mRNAs (Webb et al., 1994). 
BK,-Receptors 
Among receptor agonists, desArg'-BK has a great affinity for BK,-receptors (Regoli et ai., 
1977), while BK has low affinity for BK,-receptors (Bhoola et al., 1992). 
BK,-receptor protein contains 353 amino acid residues and couples to a G-protein for its function. 
There is 36% homology in amino acid sequence between BK,- and BKj-receptors. The cloned 
BK,-receptors have high affinity for desArg'°-kallidin, but not for BK. The binding of desArg'"-
kallidin is antagonized by desArg'^Leu'-kallidin, a BK,-receptor antagonist. Therefore, the 
expressed receptors have the pharmacological characterics of BK,-receptors (Menke et al., 1994). 
Under normal condition, BK,-receptors seem to be absent, but are expressed in smooth 
muscle cells, fibroblasts, and pain fibers in some pathological states, e.g., inflammation and tissue 
damage (Regoli et al., 1981; Perkins and Kelly, 1993), and are expressed in isolated rabbit 
vascular smooth muscle in a time-dependent manner (Barabe et al., 1982; deBlois et al., 1991). 
DesArg'-BK, a BK,-receptor agonist, relaxes the aorta smooth muscle of rabbits, an action that is 
mediated by prostaglandins, but it also contracts the rabbit aorta by direct effect on BJij-receptors 
(Churchill and Ward, 1986; 1987). The functions of BK,-receptors are modulated by interleukins 
(Regoli et al., 1993). The activation of BK,-receptors increase the release of IL-1 and TNF (tumor 
necrosis factor) from macrophage cells (Tiffany and Burch, 1989). IL-I is the endogenous trigger 
for the induction of BK,-receptors and the mediator for increasing the effect of desArg' BK in 
inflammation (deBlois et al., 1991). 
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BKj -Receptors 
BKj-receptors have high affinity for BK and kallidin, but do not respond to desArg'-BK or 
other related peptides (Bhoola et al., 1992). Most of the actions of kinins are mediated through 
the BKi-receptors which are responsible for arterial vasodilation, plasma extravasation, pain, and 
the release of prostaglandins, EDRF, and catecholamines (Regoli et al., 1993). The muscle 
relaxation in the dog carotid artery (Regoli et al., 1986), rabbit mesentery artery and human basilar 
artery (Nwator and Whalley, 1989; Whalley et al., 1987) and the venoconstriction in rabbit jugular 
vein are all mediated by BKj-receptors. 
BKi-receptor has 366 amino acid residues with a molecular weight of 41 KDa, three N-
linked glycosyiation sites, and a Ser318 as a protein kinase A phosphoiylation site. The receptor 
protein has high homology with seven-transmembrane domain G protein-coupled family 
(McEachem et al., 1991). Human BK2-receptor cDNA has 84% homology with mouse BK,-
receptor genomic DNA. Both genes have been expressed in a mammalian cell line, COS-7 cells, 
which lack endogenous BK receptors. The expressed receptor protein has the same properties of 
BKj-receptor, including high binding affinity with BK (Kj, = 0.13 nM), seven-transmembrane 
domains and coupled to G-protein (Hess et al., 1994). But the gene cloned from human genomic 
library encodes a receptor protein with 364 amino acid residues forming seven-transmembrane 
domains, shares high identity with rat and mouse Bl^-receptors, and is found in most human 
tissues (Ma et al., 1994). 
Other Receptors 
Because the BK-induced contraction of guinea pig tracheal and lung parenchymal strips 
can not be totally abolished by BK,-receptor blocker, desArg'Leu' -BK or BKj-receptor blocker, 
D-ArgHyp^D-Phe'-BK (NPC 567). Thus another BK-receptor (BI^) may exist in pulmonary 
tissues, particularly in the large airways (Farmer et al., 1989). However, Bl^-receptors have not 
been molecularly characterized. 
The subtypes of BKj-receptors may also exist in intestinal epithelium cells, fibroblasts, and 
primary brain cultures (Lewis et al., 1985; Braas et al., 1988). Two subtypes of Bl^-receptors 
have been characterized by pharmacological studies from smooth muscle and neuron, respectively. 
The smooth muscle subtype has lower affinity for BK, but has higher affinity for the BK analogue, 
Thi' ',D-Phe'-BK which is an antagonist for the smooth muscle subtype and is an agonist for the 
neuronal subtype (Hess et a!., 1992). 
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Table 1. Kinin receptors in isolated preparations and culture cells (Bhoola et al., 1992) 
R«eptar type EfTec; 
Isolated tissues 
Rat 
Duodenum BK2 Relaxation 
Vas deferens BK2 Contraction 
Uterus BK2 Contraction 
Rabbit 
.•\orta B K l '  Contraction 
Jugular vein BK2 Contraction 
Guinea pig 
Trachea 
•r epithelium BK2 Relaxation 
— epithelium BK2 Contraction 
Ileum BK2 Contraction 
Dog 
Renal artery BK2 Relaxation 
Carotid artery BK2 Relaxation 
Bladder . BK2 Contraction 
Cell type 
Human fibroblasts BK2 Ca'* increase, cell division 
Murine neuroblastoma (NlE-Ho) BK2 cGMP increase, phospholipase -A., activation 
Murine neuroblastoma x glioma (NG108-15) BK2 Phosphotidylinositol turnover, Ca-* and cGMP 
increase 
Bovine aortic endothelial cell BK1/BK2 cGMF increase 
Bovine pulmonary artery endothelial cell BK2 EDRF release and Ca-* increase 
Murine macrophages (P388-D1 RAW 264.7) BKl IL-1, TNF release 
Murine 3T3 fibroblasts BK2 FOE, synthesis 
Madin-Darby canine kidney cells BK2 Phospholipase A] activation, arachidonic acid 
release 
Antagonists 
The design and synthesis of new specific antagonists have been obtained from structure-
activity analysis by Sterwart and Vavrek. Thus, by replacing the Proline' residue of BK with a D 
phenylalanine, the agonistic activity of BK is converted into antagonistic activity on the guinea pi 
ileum (Vavrek and Stewart, 1985). In addition, BK and its antagonists can be converted into BI^-
receptor agonist or antagonists respectively, by carboxypeptidase (Regoli et al., 1986). 
The potent action of desArg'-BK on the isolated rabbit aorta is antagonized by 
desArg'Leu*-BK (Regoli et al., 1986). Thus, desArg',Leu®-BK is a BK,-receptor blocker. The 
antagonist, NFC 567 (D-ArgHyp^Thi'-®,Phe''-BK) is a potent BK,-receptor blocker. The 
replacement of D-phenylalanine for proline increases resistance to peptidase, and the inclusion of 
(3-2-thienylalanine enhances potency (Bhoola et al., 1992). 
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In addition, another antagonist, HOE 140 (D-Arg[Hyp^,Thf,D-Tic', Oic']-BK) is a potent 
specific BKj-receptor blocker which has high binding affinity for BK-receptors on guinea pig 
ileum membranes and has a prolonged half-life (Hock et al., 1991; Wirth et al., 1991; Brenner et 
al., 1993). The potency of HOE 140 is 40 times greater than that of NPC 567. 
HOE 140 inhibits BK-induced hypotension in the rat, bronchoconstriction in the guinea 
pig, and the carrageenin-induced inflammation in the rat paw (Wirth et al., 1991). HOE 140 also 
inhibits BK-induced contractions in the guinea pig ileum and pulmonary artery, and in the rat 
uterus. However, the contraction induced by desArg®-BK in the rabbit aorta is not inhibited by 
HOE 140 (Hock et al., 1991; Wirth et al., 1991). Therefore, HOE 140 is considered as a selective 
BKj-receptor antagonist. 
The hypothesis that the C-terminal (3 turn structure of BK is required for the binding with 
BK receptors, has led to the design of new agonists and antagonists with more specific and higher 
binding affinity (Kyle et al., 1994). 
Mechanisms of Action 
Kinins may promote one or more of the following cellular signal transduction pathways: a) 
activation of phospholipase C (PLC) which results in the formation of inositol 1,4,5-trisphosphate 
(IP3) and diacylglycerol (DAG) (van Blitterswijk et al., 1991), and Ca*"^ mobilization through 
elevated IP3 concentration (Takeuchi et al., 1988; Simeone et al., 1995); b) an increase in chloride 
transport in rat colonic epithelia (Cuthbert and Margolius, 1982); c) formation of EDRF, nitric 
oxide (NO) (Liao and Homey, 1993); d) activation of phospholipase A2(PLA2) which forms 
arachidonic acid, prostaglandins, and leukotrienes (Burch and Axelrod, 1987); e) stimulation of 
adenylyl cyclase which leads to an increase in intracellular cAMP concentration (Gadd and 
Bhoola, 1988); and f) other pathways. 
The linkage of BK receptors to a second messenger system is through a family of G 
proteins. Different cellular responses produced by BK may occur because of different binding 
affinity to the receptors and different signal transduction pathways or species difference (Hess et 
al., 1994). In comparing human and mouse BKj-receptors, both receptors have similar binding 
affinity for agonists, but they differ in their binding affinity for antagonists. Thus, species 
difference can produce variation in pharmacological responses (Hess et al., 1994). 
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Phospholipase C (PLC) and Mobilization 
BK increases [Ca^"^]; in several tissues. In vascular smooth muscle, the BK-induced 
increase of [Ca^^]; is mediated by the receptor-coupled activation of PLC which hydrolyzes inositol 
biphosphate, releases IP3 and DAG. The elevated IP3 then mobilizes [Ca^"^]; from the intracellular 
Ca^"^ stores of endoplasmic reticulum (Takeuchi et al., 1988; Simeone et al., 1995). In bovine 
pulmonary endothelial cells, both BK, agonist (desArg'-BK) and BKj agonist (BK) evoke similar 
responses (Smith et al., 1995). The effect of PLC can be antagonized by an aminosteroid U-
73122 (Simeone et al., 1995) which abolishes BK-induced [Ca"^]; release, but a structural 
analogue, U-73343, does not (Jin et al., 1994). 
In Ca^^ free medium, BK induces only a small transient Ca^^ peak which is primarily due 
to a release from endoplasmic reticulum (Fasolato et al., 1988) and thus is called release-phase. 
After Ca*"" is re-added in the same test sample with the presence of BK, it induces another 
sustained increase of [Ca^"^]; which results from the influx of extracellular Ca^^ (Fasolato et al., 
1988) and thus is called influx-phase or second-phase. Furthermore, in Ca^"^ containing medium, 
BK induces a biphasic increase of [Ca^^]), an initial, large transient Ca^^ spike followed by a lower 
sustained Ca^^ increase (Buchan and Martin, 1991). The Ca^^ influx occurs only after the initial 
release of Ca^"^ from internal stores (Yang et al., 1994). Therefore, the Ca^^ release from 
intracellular stores causes the first transient peak, which is followed by Ca^"^ influx from the 
extracellular medium (Buchan and Martin, 1991). However, part of the elevated [Ca^^^Jj may be 
due to a release from an IPj-insensitive Ca^"^ pool caused by Ca^'^-induced Ca release (Islam et 
al., 1992). 
In NG108-15 cells, BK (30 nM) completely depletes the IPj-sensitive [Ca^"^]; store within 1 
min. The refilling of the IPj-sensitive [Ca^^^Jj stores requires the presence of extracellular Ca^^ and 
is blocked by La'"^ (Lo and Thayer, 1993). Also, the Ca^'^-Mg^'^-ATPase inhibitor, thapsigargin, 
irreversibly depletes the [Ca^^], stores and prevents their refilling. Thus, the IPj-sensitive [Ca^"^]; 
store is refilled by cytoplasmic Ca^"^ through a thapsigargin-sensitive Ca^^-Mg^^-ATPase and the 
cytoplasmic Ca^^ is refilled by extracellular Ca^^ through activated plasmalemmal Ca^^ channels 
(Lo and Thayer, 1993). In eukaryotic cells, the Ca^"^ influx occurs through at least three pathways: 
a) voltage-dependent Ca^^ channels (VDCCs) controlled by the change of the plasma membrane 
potential, b) receptor-operated Ca^"^ channels (ROCs), where the channels are a part of the 
receptors and are activated by the agonist binding to receptors, and c) second messenger-operated 
Ca^"^ channels (SMOCs) activated by the triggered second messengers (Meldolesi and Pozzan, 
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1987; Berridge and Irvine, 1989). The activation of VDCCs by membrane depolarization initiates 
a number of cellular responses including muscle contraction, and exocytotic secretion in endocrine 
and nerves cells. 
There are many Ca^^ channel blockers. Nimodipine is a L-type VDCC blocker 
(Baumgarten and Villereal, 1992; ZhuGe et al., 1995) vk^hich blocks the BK-induced Ca"^ influx in 
cultured human fibroblasts. SK&F 96365(1-(beta-[3-(4 methoxyphenyl) propoxyl]-4-methoxy-
phenethyl)-lH-imidazole) is a ROC blocker (Cabello and Schilling, 1993). In vascular endothelial 
cells, SK&F 96365 blocks the BK-induced Ca""" influx without affecting the release from 
internal stores (Cabello and Schilling, 1993). 
In NG 108-15 cells and NlE-115 neuroblastoma cells, BK induces a transient 
hyperpolarization which is followed by a prolonged depolarization which may be attributed to the 
dual effects of IP3 and DAG formed from the hydrolysis of phosphatidylinositol (Higashida and 
Brown, 1987). In these cells, the elevated IP3 releases Ca^"^ from intracellular stores which 
activates the Ca^^-dependent K^ channels and hyperpolarizes the plasma membrane. However, 
DAG activates protein kinase C (PKC), inhibiting voltage-dependent K"^ channels, and depolarizing 
the plasma membrane (Higashida and brown, 1986). BK initiates a biphasic increase in 
intracellular DAG concentration in human fibroblasts (Etscheid et al., 1991). It induces a transient 
DAG peak by the rapid hydrolysis of phosphoinositdes, which correlates with the accumulation of 
IP3 and elevation of [Ca^"^];, followed by a decline to near basal levels, then a second rise to a 
plateau phase. The second plateau phase of DAG comes from the breakdown of other 
phospholipids including phosphatidylcholine. The increase of DAG also correlates well with the 
activation of PKC which phosphoiylates the substrate, 80 KDa fibroblast acidic protein 
(Etscheid et al., 1991). However, the role of PKC is still not well-understood. 
Chloride Transport 
Kinins increase intestinal smooth muscle contraction and mucosal electrolyte secretion 
(Gaginella and Kachur, 1989). BKj-receptors mediate the BK-induced CI" secretion in rats and 
rabbit colonic epithelial cells (Cuthbert and Margolius, 1982), or rabbit and guinea pig ileum 
(Gaginella and Kachur, 1989). Therefore, the activation of BKj-receptors may be involved in 
contraction and secretory processes of the ileum (Gaginella and Kachur, 1989). 
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Nitric Oxide (NO) 
Kinins stimulate the formation of NO in vascular endothelial cells (Liao and Homey, 1993; 
Blatter et al., 1995), tracheobronchial epithelial cells, neurons, neutrophils, and macrophages 
(Salvemini et al., 1989). NO is produced from L-arginine by Ca^Vcalmodulin-dependent NO 
synthase (NOS) (Blatter et al., 1995). The liberated NO plays a role as a signaling molecule 
which is involved in neuronal cell ftinction, such as the release of neurotransmitter, gene 
transcription, and neurotoxicity (Clementi et al., 1995). 
Both Ga, and Ga^ are coupled to BK receptors in bovine aortic endothelial cells but the 
BK-induced NO release is mediated by Ga^ which is insensitive to pertussis toxin (PTX) (Liao 
and Homey, 1993). In cultured bovine aortic endothelial cells, BK produces a transient increase in. 
[Ca^"^]i followed by a transient increase in intracellular NO (Blatter et al., 1995). NO may: a) 
stimulate guanylyl cyclase and transiently increase cGMP level; b) recruit Ca^"^, and c) enhance the 
turnover of phosphatidyl-inositol (Bhoola et al., 1992). 
Phospholipase A2 (PLA,) 
BK stimulates the synthesis of prostaglandin Ej (PGEj) in murine 3T3 fibroblasts. The 
synthesis of PGEj is mediated through the activation of BK-receptors which are coupled to a 
PTX-insensitive G-protein. Then G-protein activates both PLC and PLAj, and the activated PLAj 
releases arachidonate for the synthesis of PGEj (Burch and Axelrod, 1987). 
At 37°C, the formation of lysophosphatidyl-inositol (lyso-PI) is as early as the formation 
of IP3. Thus, PLC and PLAj are activated at the same time. But at 30°C, lyso-PI is formed 
before the increase of IP3, thus the activation of PLAj does not require the rise of IP3. Also the 
formation of unesterified arachidonic acid occurs earlier than that of DAG. Therefore, the BK-
stimulated activation of PLAj is independent of the activation of PLC (Kaya et al., 1989). 
However, DAG increases the activity of PLAj and enhances the synthesis of PGE^ (Burch, 1988) 
and the BK-induced amplification of PLA2 is mediated by DAG independently of PKC (Burch et 
al., 1988). The BK-induced PGEj synthesis is potentiated more than 10-fold by interleukin-1 
(Burch et al., 1988). 
Adenylyl Cyclase 
In lung membrane of guinea pigs, BK evokes a dose-dependent increase in cAMP by the 
stimulation of adenylyl cyclase (Gadd and Bhoola, 1988). BK-induced increase of cAMP requires 
the presence of extracellular Ca^* in cultured rat sympathetic neurons. Therefore, BK activates the 
metabolism of phosphoinositide and elevates cAMP concentration (Suidan et al., 1991). In 
cultured arterial smooth muscle cells, chronic exposure to cAMP, cholera toxin, forskolin the 
adenyl cyclase activator or the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) 
increases the number of cell surface BK receptors and the hydrolysis of phosphatidylinositol. 
Thus, cAMP enhances the synthesis of new BK receptors (Dixon, 1994). In D384-human 
astrocytoma cells, BK inhibits the formation of cAMP and the effect is mediated by a Ca^-
dependent inhibition of adenylyl cyclase (Altiok and Fredholm, 1993). 
Other Mechanisms 
In vascular endothelial cells, BK induces the tyrosine phosphorylation of two low 
molecular weight proteins which are 42- and 44-KDa isoforms of mitogen-activated protein kinase 
(MAP kinase) (Fleming et al., 1995; Demolle et al., 1988).). In Swiss 3T3 cells, BK induces the 
tyrosine phosphorylation of focal adhesion-associated protein such as pl25FAK and paxillin (Leeb-
Lundberg et al., 1994). Also, the phosphorylation of serine or threonine in the cytoplasmic 
segment of BK receptors may relate to the desensitization of BK (Roberts and Gullick, 1989). 
Interactions of Kallikrein-Kinin with Islet Hormones 
The whole pancreas is an integrated organ, in which the exocrine and endocrine tissues are 
closely interrelated for optimal functional activities. Although acinar cells and islet cells secrete 
different compounds into different locations, there is documented interaction between these two 
types of cells. The dispersion of the small islets throughout the exocrine tissue may provide a 
considerable contact between exocrine and endocrine pancreas for promoting interaction. 
As mention previously, islet cells secrete insulin, glucagon, somatostatin and other 
hormones (Hazelwood, 1989) to control glucose homeostasis while pancreatic acinar cells secrete 
more than 20 different enzymes including kallikrein for processing precursor proteins (Seidah et 
al., 1988). Tissue kallikrein exists in pancreatic islets and acini with the majority of the enzyme 
being in the acini (Pinkus et al., 1983). In fact, the pancreas is one of the richest sources of tissue 
kallikrein (Bhoola, 1992) and the substrate, kininogens, are abundant in the pancreas (Barbe et al., 
1988). In addition, circulatory HWK binds to vascular endothelium and plasma kallikrein can 
release BK from the endothelial-bound HWK (Nishikawa et al., 1992). 
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However, the physiological function of kallikreins and kinins in the pancreas is still not 
well-understood, except that tissue kallikrein may be involved in the formation of insulin from 
proinsulin (Ole-Moiyoi et al., 1979), and BK may aggravate acute pancreatitis induced by cerulein 
in rabbits (Yotsumoto et al., 1993). In diabetic patients, the tissue kallikrein-kinin system is 
suppressed, but the plasma kallikrein-kinin system is activated depending on the degree of the 
impairment of glucose metabolism (Uehara et al., 1988). 
Influences of Islet Hormones on Glucose Homeostasis 
Glucose is the major energy source for cellular metabolism. The concentration of glucose 
in the blood is controlled by the actions of insulin and glucagon, and the secretion of these two 
hormones is regulated by the presence of somatostatin. Insulin increases glucose transport in 
muscle and adipocytes, and glycogen synthesis in liver and muscle. In addition, it also stimulates 
the expression of a variety of intracellular enzymes and the transport systems for glucose (White 
and Kahn, 1994). 
Glucagon is responsible for the breaking down of glycogen to release glucose from liver 
and adipose tissue by activating cAMP and initiating phosphoryation of glycogen. In addition, 
glucagon regulates glucose homeostasis by stimulating the release of insulin and somatostatin, and 
insulin inhibits glucagon secretion (Samols and Harrison, 1976). 
Pancreatic islets synthesize and release both SS-14 and SS-28 which lower the levels of 
cAMP and inhibit arginine-induced release of insulin and glucagon, and regulate the ratios of 
insuHn/glucagon (Hazelwood, 1989). 
Influences of Kallikrein-Kinin on Glucose Homeostasis 
A hypoglycemic effect caused by kallikrein was first reported by Frey in 1932. 
Administration of kallikrein into human patients with non-insulin-dependent diabetes mellitus 
(NIDDM; type II diabetes) (Wicklmayr and Dietze, 1977) or into pancreatectomized dogs (Bhoola 
et al., 1992) results in a decrease in the plasma glucose concentration. In addition, BK reduces the 
blood glucose concentrations in postoperative patients by increasing whole body glucose uptake 
(Jauch et al., 1986). 
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Kinins also improve blood reperfusion, oxygenation, and the transport of glucose in 
isolated ischemic hearts (Needleman et al., 1975) and in isolated perfused hearts (Rosen et al., 
1983). In alloxan-induced diabetic rats, captopril, an inhibitor of angiotensin-converting enzyme, 
protects the breakdown of kinins and potentiates the BK-induced glucose-lowering activity and 
markedly decreases the blood glucose concentration (Jaffa et al., 1986). 
In isolated rat adipocytes, BK increases hexose transport under the presence of insulin in a 
dose-dependent manner. In obese Zucker rats, captopril also enhances insulin-induced glucose 
transport in skeletal muscle by improving the disposal of glucose. The infusion of BK improves 
insulin activity in patients with postoperative stress syndrome, in which insulin resistance is due to 
a postoperative receptor defect in skeletal muscle (Dietze, 1982). The modulatory action of BK on 
insulin may occur at post-insulin binding sites (Goldman et al., 1987). 
BK reduces the production of endogenous glucose, and is accompanied by a significant 
reduction of glucose, lactate, pyruvate, and alanine in arteries of surgical stressed patients (Jauch et 
al., 1988). The infusion of BK does not change the glucagon-induced rise in hepatic glucose and 
glucose cycling, but in the later stage, BK decreases the production of glucose induced by 
glucagon (Hartl et al., 1989). These results suggest that BK regulates the availability and 
utilization of glucose in the target tissues by enhancing the uptake of glucose, improving insulin-
induced glucose transport, decreasing the glucagon-induced rise of glucose or reducing 
gluconeogenesis (Jauch et al., 1989). 
The infusion of BK doubles the muscle glucose uptake without a change in the formation 
of lactate (Jauch et al., 1989) and BK fails to stimulate glucose metabolism in the isolated soleus 
muscle of rat (Shimojo et al.,1987). In addition, BK increases glucose oxidation only in the 
presence of insulin in rat adipocytes (Symington et al., 1988). Therefore, it seems that kinins do 
not have direct actions to increase glucose uptake and utilization. 
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CHAPTER 2. STIMULATORY EFFECT OF BRADYKININ ON 
INSULIN RELEASE FROM THE PERFUSED RAT PANCREAS 
A paper published in the American Journal of 
Physiology 268; E1027-1030, 1995 
Chi Yang and Walter H. Hsu 
Abstract 
Rat pancreas perfusion was performed to study the effect of bradykinin (BK) on insulin 
release. At the perfusate glucose concentration of 6 mM, BK (0.01 - 1 nM) increased insulin 
release in a concentration-dependent manner. In addition, BK (1 jiM) increased the glucose (10 
mM)-induced insulin release. HOE140 (0.1 nM), a BK-receptor antagonist, decreased the 
baseline insulin release and abolished the BK (1 nM)-induced increase in insulin release. In 
addition, HOE140 (0.1 |iM) attenuated the glucose (10 mM)-induced increase in insulin release. 
Because the blockade of BK receptors by HOE 140 attenuated the glucose-induced increased 
insulin release, our present findings suggest that BK could play a physiological role in the 
regulation of insulin release. 
Introduction 
Kinins including bradykinin (BK) display an extraordinarily high degree of physiological 
activity. They are the most potent vasodilator autacoids of mammals and they increase capillary 
permeability, produce edema, influence blood pressure and local blood flow, evoke pain and 
reflexes by acting on nerve endings, increase chloride and glucose transport, cell proliferation and 
other cellular functions (Bhoola et al., 1992). Kinins stimulate the release of hormones, e.g., renin 
from the kidney (Beierwaltes et al., 1985), vasopressin from the posterior pituitary gland (Baertschi 
et al., 1981), growth hormone and prolactin from the anterior pituitary cells (Drouhault et al., 
1987; Jones et al., 1988), and catecholamines from the adrenal medulla (Staszewska-Barczak and 
Vane, 1967). 
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Activation of the kallikrein-kinin system induces hypoglycemia (Frey et al., 1932; 
Wicklmayr and Dietze, 1977). The administrations of kallikrein, the enzyme which catalyzes the 
formation of kallidin and BK, to human patients with non-insulin-dependent diabetes mellitus 
(NIDDM) (Wicklmayr and Dietze, 1977) or pancreatectomized dogs (Frey et al., 1932) result in a 
decrease in the plasma glucose concentration. The infusion of BK improves insulin activit>' in 
human patients with postoperative stress syndrome (Dietze et al., 1978; Dietze, 1982). In addition, 
BK increases glucose oxidation in adipocytes isolated from both normal and streptozotocin-induced 
diabetic rats (Symington et al., 1988). These findings indicate that BK directly promotes glucose 
utilization by cells. 
The pancreas is one of the richest sources of tissue kallikrein (Bhoola et al., 1992) that is 
found in both islets and acini with most present in acini (0rstavik et al., 1980; Pinkus et al., 
1983). However, the function of the kinin system in the pancreas is not well-understood, except 
that tissue kallikrein could be involved in the formation of insulin from proinsulin (Ole-Moiyoi et 
al., 1979) and that BK may aggravate acute pancreatitis induced by cerulein in rabbits (Yotsumoto 
et al., 1993). 
In a preliminary study, we found that two kinins, BK and kallidin, increased insulin release 
in the perfused canine and rat pancreata (unpublished results). Since BK, but not kallidin, is the 
physiological kinin in rats (Bhoola et al., 1992), the present study was undertaken to further 
investigate the stimulatory effect of BK on insulin release in the perfused rat pancreas. 
Materials and Methods 
Male Sprague-Dawley rats (320-400 g) were used in these experiments. The in situ 
perfused rat pancreas preparation with an open system was performed at 37°C using a modified 
method of Grodsky and Fanska (1975). The rats were anesthetized with pentobarbital Na (60 
mg/kg, i.p.. Fort Dodge Labs, Fort Dodge, lA) and their celiac arteries and portal veins were 
cannulated with polyvinyl tubings (0.625 mm, i.d.). The rats were maintained at 37° C during the 
experiment. The Krebs-Ringer bicarbonate buffer (KRB), supplemented with 10 mM HEPES, 6 
mM glucose, and 0.2% bovine serum albumin (pH 7.4), was used as the perfusate (basal medium). 
This solution was continuously aerated with 95% Q-5% COj. In our preliminary experiments, 
this medium with a flow rate of 1 ml/min did not cause noticeable edema or impair insulin release 
during the 60 min of perfusion. 
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In the present study, the first 10 min of perfusion was considered as an equilibration 
period. Subsequently, a fraction of the effluent fluid was collected every min from the cannula of 
the portal vein. In experiment 1, after a baseline period of 10 min, the medium containing BK 
(Sigma Chemical, St. Louis, MO) was administered for 5 min followed by the basal medium. In 
experiment 2, after a baseline period of 5 min, the medium containing 10 mM glucose was 
administered for 5 min followed by the basal medium for another 5 min for the washout. 
Subsequently, glucose (10 mM) with or without BK (1 fiM) was administered for 5 min and 
followed by the basal medium for the washout. In experiment 3, after a baseline period of 5 min, 
the medium containing a BKj-receptor antagonist HOE 140 (0.1 ^M) (D-Arg[Hyp',Th?,D-
Tic',Oic']BK, donated by Hoechst-Roussel Pharmaceuticals, Somerville, NJ) was administered for 
5 min followed by HOE140/1 nM BK for another 5 min and the basal medium for the last 5 min 
for the washout. In experiment 4, after a baseline period of 5 min, the medium containing 10 mM 
glucose was administered for 5 min followed by the basal medium for the washout. Subsequently, 
0.1 nM HOE140 was administered for 5 min and was followed by HOE140/glucose for another 5 
min and the basal medium for the last 5 min for the washout. In all experiments except for the 
ones having 10 mM glucose, 15 mM glucose was perfused at the end of the experiment to confirm 
that the tissue retained normal secretory capacity under the experimental conditions. The data 
were excluded from those experiments in which the pancreas did not respond to 15 mM glucose. 
The effluent fractions were kept at 4°C and subsequently assayed within 12 h for insulin using 
radioimmunoassay (RIA) as previously described (Hale and Randle, 1963). Rat insulin was used 
as standards for the RIA. 
Data expression and statistical analysis 
Data of effluent concentrations of insulin were expressed as a percentage of baseline (mean 
of last five baseline values) and analyzed using analysis of variance (ANOVA) to determine the 
effects of pancreas, treatment, and time. The treatment x time interaction was used as an error term 
to determine the effect of treatment. The conservative F value was used to establish significance 
for the effect of treatment. Tukey's Highly Significant Difference test was used to determine 
differences between treatments for which the ANOVA indicated a significant (P<0.05) F ratio. 
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Results 
BK (0.01 - 1 |aM) increased insulin release from the perfused rat pancreas with the onset 
time of <1 min, and reached maximum response at ^ min (Fig. 1). The BK (0.01, 0.1, 1 ^M)-
induced increases in the peak effluent concentrations of insulin were 1.5, 2.5, and 3.5 times, 
respectively, above the basal control group. 
Repeated administrations of 10 mM glucose induced a 6.5-fold increase in the peak 
effluent concentration of insulin with no significant differences between the two glucose 
administrations (Fig. 2). BK alone (1 uM) caused a 3.5-fold increase in the peak effluent 
concentration of insulin. BK significantly enhanced the effect of glucose on insulin release by 
raising the peak effluent concentration of insulin to 11.2 folds above the basal control group. 
A BKj-receptor antagonist, HOE140, blocked the BK-induced insulin release (Fig. 3). BK 
alone (1 ^M) significantly increased the effluent concentration of insulin when compared with the 
basal control group. Pretreatment with HOE140 (0.1 (iM) significantly lowered the insulin level 
when compared with the basal control group. This pretreatment further abolished the BK (1 jiM)-
induced increase in insulin release. In fact, the HOE 140 + BK group had significantly lower 
effluent insulin concentrations than the basal control group. 
The effect of HOE140 on the glucose-induced increase in insulin release is depicted in 
Fig. 4. Repeated administrations of 10 mM glucose induced a 6.8-fold increase in the peak 
effluent concentration of insulin with no significant differences between the two glucose 
administrations. HOE140 (0.1 |j.M) significantly lowered the baseline insulin level and 
significantly attenuated the glucose-induced increase in the effluent concentration of insulin by 
31%. 
Discussion 
BK (0.01 - 1 (J.M) evoked insulin release from the perfused rat pancreas in a dose-
dependent manner. Although the pancreatic concentrations of kinins are not known, this effect of 
bradykinin may be physiologically significant, since in other tissues, e.g., the submaxillary gland 
(Scicli et al., 1983) and kidney (Barabe et al., 1982), concentrations of BK are detectable in the 
range of ng/mg protein. The pancreas is one of the richest sources for tissue kallikrein (Bhoola et 
al., 1992) and thus pancreatic kallikrein should promote the formation of kinins in this organ. 
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Fig. 1. Effect of bradykinin (BK) on insulin release from the perfused rat pancreas. In this and 
subsequent figures, a 10-min equilibration period preceded time 0. after a baseline period of 10 
min, BK (shown in the heavy line) was administered for 5 min followed by the basal medium. 
Values are shown as mean ± SE (n=6). The baseline effluent concentrations of insulin were 6.6 
0.5, 7.0 ± 0.6, 8.3 ± 0.7, and 7.0 ± 0.6 ng/ml for the control, 0.01 jiM, 0.1 fiM, and 1 |i.M BK 
groups, respectively. 
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Fig. 2. Enhancement by bradykinin (BK) of the glucose-induced insulin release in the perfused rat 
pancreas. After a baseline period of 5 min, 10 mM glucose was administered for 5 min followed 
by the washout for another 5 min. Subsequently, glucose (10 mM) with or without BK (1 ^M) 
was administered for 5 min. The presences of treatments are indicated by heavy lines. Values are 
shown as mean ± SE (n=6). The baseline effluent concentrations of insulin were 6.6 ± 0.5, 6.3 ± 
0.7, 7.1 ± 0.6, and 5.2 ± 0.4 ng/ml for the basal control, glucose control, BK, and glucose + BK 
groups, respectively. 
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Fig. 3. Effect of HOE140 on the basal and bradykinin (BK)-induced insulin release in the 
perfused rat pancreas. After a baseline period of 5 min, 0.1 |iM HOE was administered for 5 min 
followed by HOE/1 [.iM BK for another 5 min. The presences of treatments are indicated by 
heavy lines. Values are shown as mean ± SE (n=6). The baseline effluent concentrations of 
insulin were 6.6 ± 0.5, 7.1 ± 0.6, and 7.7 ± 0.3 ng/ml for the basal control, BK, and HOE 140 + 
BK groups, respectively. 
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Fig. 4. Effect of HOE 140 on the basal and glucose-induced insulin release in the perfused rat 
pancreas. After a baseline period of 5 min, 10 mM glucose was administered for 5 min followed 
by a washout. Subsequently, 0.1 |aM HOE was administered for 5 min and was followed by 
HOE/glucose for another 5 min. The presences of treatments are indicated by heavy lines. Values 
are shown as mean ± SE. The baseline effluent concentrations of insulin were 6.6 ± 0.5, 8.0 ± 
3.2, and 6.6 ± 0.7 ng/ml for the basal control (n=6), glucose control (n=5), and HOE 140 + glucose 
(n=4) groups, respectively. 
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Further studies are needed to determine the pancreatic concentrations of BK in rats under different 
experimental conditions. This information will help to determine the physiological significance of 
BK in stimulating insulin release. 
Most of the kinin action is mediated through BK,-receptors (Bhoola et al., 1992), while 
BK,-receptors seem to be absent normally, with expression in smooth muscle cells, fibroblasts, and 
pain fibers evident only in pathological states, e.g., inflammation (Bhoola et al., 1992) and in the 
rabbit isolated vascular smooth muscle de novo in a time-dependent manner (Barabe et al., 1982). 
The stimulatory effect of BK on insulin release may be mediated by BKj-receptors, since a 
specific BKj-receptor antagonist, HOE140 (0.1 ^iM), abolished this effect of BK. Also, 0.1 ^.M of 
HOE 140 has been shown to block maximally the effects of kinins mediating through BK2-
receptors in other tissues (14). In addition, we found that HOE140, but not a BKj-receptor 
antagonist des-Arg',[Leu']-BK (1 fxM), antagonized the BK-induced insulin release from a clonal 
P-cell line RINmSF (unpublished results). 
In the present study, HOE 140 not only abolished the BK-induced insulin release, but it 
even lowered the baseline insulin release and attenuated the glucose-induced insulin release. The 
HOE140-induced inhibition of insulin release probably is due to a specific effect on P-cells which 
blocks the influence of endogenous BK, since this drug did not inhibit insulin release in vitro from 
RINmSF cells (unpublished results). Therefore, our findings further suggest that kinins sm their 
receptors could play an important role in the regulation of insulin release. However, more studies 
are needed to establish the physiological significance of kinins in stimulating insulin release. In 
particular, the dose-response characteristics of HOE 140 on the BK effect, baseline and glucose-
stimulated insulin release will help to establish this physiological significance. 
Since the acini contain most of the tissue kallikrein found in the pancreas, it is likely that 
the acinar kinins can alter insulin secretion from the P-cells of the islet. To date, there is no direct 
evidence that acinar tissues affect islet function, but clinical observations support this premise. 
Human patients with chronic pancreatitis or acinar atrophy develop glucose intolerance as a result 
of insufficient insulin release (Bendayan, 1990). This reduction in insulin release may be due to a 
lack of the acinus-islet interaction, because the reduction of P-cell numbers in these human patients 
appears too small to explain the impaired insulin secretion in response to various stimuli (Vinik 
and Jackson, 1980). In addition, pancreatic acinar atrophy is induced with a Cu^^-deficient diet in 
rats (Folsch et al., 1988). Both the baseline and glucose-stimulated plasma insulin concentrations 
of these rats were lower than the controls despite the fact that the insulin content of the islets was 
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not significantly different between normal rats and rats with acinar atrophy (Folsch et al., 1988). 
Future studies using the acinar atrophy model may gain an insight into the physiological role of 
kinins in the regulation of insulin release. 
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CHAPTER 3. GLUCOSE-DEPENDENCY OF BRADYKININ-INDUCED 
mSULIN SECRETION FROM THE PERFUSED RAT PANCREAS 
A paper to be submitted to the American Journal of Physiology 
Chi Yang and Walter H. Hsu 
Abstract 
In order to investigate the glucose dependency of bradykinin (BK)-induced insulin 
secretion, rat pancreata were perfused in situ with BK (1 |iM) for 30 min in the presence of 
glucose concentrations of 1 - 20 mM. Glucose (6 mM) alone induced a steady basal insulin 
secretion which was 6.7 ± 0.5 ng/ml. Glucose of 1 mM gradually decreased insulin secretion to ~ 
30-40% of the baseline level in which insulin secretion was maintained by 6 mM glucose. 
Glucose of 10 and 20 mM induced a biphasic insulin secretion, characterized by a transient peak 
and a sustained phase; the sustained phase was higher than the transient peak. Glucose of 20 mM 
induced a higher insulin secretion than 10 mM glucose. When BK was administered in 1 mM 
glucose, it induced a transient insulin release peak which was ~ 2.8-fold of the baseline level, then 
the insulin concentrations of the effluents decreased gradually to the levels which were slightly 
higher than that of the 1 mM glucose alone, but lower than the baseline level. After BK was 
administered in 6 mM glucose, it induced a transient insulin release peak which was ~ 3.6-fold of 
the baseline, and followed by a sustained insulin secretion phase which was significantly higher 
than that of the 6 mM glucose control group, but lower than the transient peak. When BK was 
perfused with 10 mM or 20 mM glucose, it induced a similar insulin secretion pattern as in 
glucose (10 or 20 mM) alone. However, the combination of glucose and BK induced a higher 
transient insulin release peak, about 7.8- and 12-fold of the baseline, respectively. Also, the BK-
glucose-induced sustained phase was higher than the transient peak. BK induced a greater 
potentiation of insulin secretion in 20 mM glucose than in 10 mM glucose. Taken together, our 
findings suggest that BK induced insulin secretion from rat pancreata in a glucose-dose-dependent 
manner. The higher the glucose concentration, the greater the potentiation in BK-induced insulin 
secretion. Since the sustained insulin secretion phase is due to increased synthesis of insulin, BK 
may stimulate both the synthesis and release of insulin. 
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Introduction 
Kinins, including bradykinin (BK), display an extraordinarily high degree of physiological 
activities (Pisano and Austin, 1974). They influence a number of biological processes, including 
blood pressure and local blood flow (Nwator and Whalley; 1989; Pan et al., 1993), pain (Steranka 
et al., 1988) and inflammation (Figueroa,1990), increased vascular permeability and local edema 
(Carter et al., 1974), contraction of smooth muscle (Collier et al., 1962), decreased blood glucose 
concentration (Wicklmayr and Dietze, 1977), promotion of cell proliferation (Goldstein et al., 
1984; Marceau and Tremble, 1986), increased glucose uptake by intact intestine (Sharp and 
Debnam, 1992; Kellett and Barker, 1989), and other cellular functions. 
Kinins also stimulate the release of hormones, e.g., renin from the kidney (Beierwalres et 
al., 1985), vasopressin from the posterior pituitary gland (Baertschi et al., 1981), growth hormone 
and prolactin fi-om the anterior pituitary gland (Drouhault et al., 1987; Jones et al., 1988) and 
catecholamines from the adrenal medulla (Staszewska-Barczak and Vane, 1967). The effects of 
BK are mediated by at least two groups of BK receptors, BK, and BKj, but the latter mediates 
most of the effects of BK (Roberts, 1989). 
BK reduces blood glucose concentrations in post-surgical patients (Jauch et al., 1986) and 
in isolated ischemic hearts (Needleman et al., 1975) by enhancing glucose uptake, improving 
insulin-induced glucose transport, decreasing glucagon-induced glucose production and reducing 
gluconeogenesis (Jauch et al., 1989). In alloxan-diabetic rats, captopril, an inhibitor of 
angiotensin-converting enzyme, inhibits the breakdown of kinins, thereby potentiating BK-induced 
hypoglycemia (Jaffa et al., 1986). In addition, BK increases glucose oxidation in adipocytes 
isolated from both normal and streptozotocin-induced diabetic rats (Symington et al., 1988). Thus, 
BK directly promotes glucose utilization by cells. 
BK may regulate glucose metabolism by increasing insulin secretion. In our previous 
study, administration of BK for 5 min caused a dose-dependent increase in insulin secretion which 
was mediated by BKj-receptors (Yang and Hsu, 1995). BK also enhanced glucose-induced insulin 
release. The specific BKj-receptors blocker, HOE 140, reduced the basal insulin secretion, 
abolished the BK-induced insulin secretion, and attenuated the glucose-induced insulin secretion. 
These results indicated that endogenous bradykinin plays a physiological role in maintaining the 
basal and glucose-induced insulin secretion (Yang and Hsu, 1995). However, the glucose-
dependency of BK-induced insulin secretion remains unknown. 
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In the present study, the rat pancreas was perfused with BK for 30 minutes in the presence 
of various glucose concentrations to investigate the effect of BK and if BK-induced insulin 
secretion was glucose-dependent. 
Materials and Methods 
Male Sprague-Dawley rats (300-400 g) were anesthetized with pentobarbital sodium (60 
mg/kg ip; Fort Dodge Labs, Fort Dodge, I A) and kept on a 37°C hot plate. The rat pancreatic 
perfiision was performed as previously described (Yang and Hsu, 1995). After celiac arteries were 
cannulated, the rat pancreata were immediately perfused in situ with oxygenated (95% O^ISVo COj) 
Krebs-Ringer bicarbonate (KRB) solution supplemented with 10 mM N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid (HEPES), 6 mM glucose, 0.2% bovine serum albumin and pH 7.4 as the 
basal medium. The perfusion rate was maintained at 1 ml/min and the effluent was collected 
every minute from the cannulated portal vein. 
After the rat pancreatic preparations were established, the first 10-15 min of perfusion was 
considered as the equilibration period. After a baseline period of 10 min, the perfusate containing 
glucose (1, 6, 10, or 20 mM) was administered for 30 min with or without BK (1 fxM) (Sigma 
Chemicals, St. Louis, MO). In our previous study, BK (0.01 - 1 ^M) dose-dependently increased 
insulin release and BK 1 |i.M induced a 3.7-fold increase of the baseline level of insulin (Yang and 
Hsu, 1995). Therefore, we used 1 ^M BK in these experiments. The effluent fractions were kept 
at 4°C and subsequently assayed within 12 h for insulin by using radioimmunoassay (RIA) as 
previously described (Hale and Randle,1963). Rat insulin was used as standards for the RIA. 
Data of effluent insulin concentrations are expressed as a percentage of the baseline level 
(mean of 10 baseline values) in means ± SE. For results in Fig. 5, the areas under the 30 min 
perfusion curve were calculated with a scanning program (SigmaScan; Jandel, Corte Madera, CA). 
Data were analyzed by using analysis of variance (ANOVA) to determine the significance of 
treatment and time. The treatment x time interaction was used as an error term to determine the 
effect of treatment. The significance of treatment was determined from the conservative F value. 
Tukey's highly significant different test was used to determine the differences between treatments 
for which the ANOVA indicated a significant (P < 0.05) F ratio. 
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Results 
The insulin secretion in the 6 mM glucose control group was maintained at a steady level 
of 6.7 ± 0.5 ng/ml (n = 4), throughout the perfusion period (Fig. 1). BK (1 fiM) induced a 
biphasic insulin secretion. The onset time of insulin secretion was less than 1 min and reached the 
peak that was ~ 3.7-fold of the baseline level at< 3 min, then the insulin levels decreased gradually 
within 5 min to a level which was still significantly higher (~ 50 %) than that of the basal level and 
maintained at this level to the end of perfusion (Fig. 1). The combination of BK and 6 mM 
glucose in insulin secretion was significantly higher than that of 6 mM glucose alone. 
Glucose of 1 mM alone reduced insulin secretion to a level of 30-40% of the baseline 
level in which insulin secretion was maintained by 6 mM glucose (Fig. 2). Administration of BK 
(1 nM) in 1 mM glucose induced a transient insulin release with a peak of 2.8-fold of the baseline 
level. Subsequently, the insulin levels decreased gradually to a level ~ 50 % of the baseline level, 
which was still slightly higher than that of the 1 mM glucose alone group (Fig. 2). Although the 
concentrations of BK plus 1 mM glucose treatment group in insulin secretion was lower than that 
of baseline level which was perfused with 6 mM glucose alone, the insulin concentrations were 
still significantly higher than that of 1 mM glucose alone. 
Glucose of 10 mM alone also induced a biphasic insulin secretion. The first transient 
insulin release peak was 7.8-fold of the baseline level at 3 min; subsequently, the insulin levels 
decreased to 4.5-fold of the baseline level within 4 min, followed by a sustained level of ~ 9-fold of 
the baseline level (Fig. 3). By comparing with the 10 mM glucose alone treatment group, the 
combination of BK and 10 mM glucose significantly increased insulin secretion which was higher 
than that of 10 mM glucose alone. It showed a similar insulin secretion pattern to that induced by 
10 mM glucose alone; BK increased insulin secretion with the first peak and sustained level of 12-
and 13,5-fold of the baseline level, respectively (Fig. 3). 
Glucose of 20 mM alone also caused a similar insulin secretion pattern to that induced by 
10 mM glucose; the first transient peak and sustained phase were 12- and 15-fold of the baseline 
level, respectively (Fig. 4). BK (1 nM) significantly enhanced 20 mM glucose-induced insulin 
secretion; the first peak and sustained phase were about 18- and 24-fold of the baseline level, 
respectively (Fig. 4). The insulin secretion of BK plus 20 mM glucose was significantly higher 
than that of 20 mM glucose alone. 
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Fig. 1. Effect of 1 fiM bradykinin (BK) in the medium containing 6 mM glucose (G) on insulin 
secretion from the perfused rat pancreas. BK was administrated for 30 min (bar). Values are 
shown as means ± SB. In this and all other figures, G of 6 mM was administered during the 
equilibration period of 10 -15 min followed by another 10 min of the baseline period. The 
baseline concentrations of insulin in the effluents were 6.7 ± 0.5 ng/ml (n = 4 rats) and 6.6 ± 0.5 
ng/ml (n = 8 rats) for 6 mM glucose alone and bradykinin + glucose groups, respectively. 
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Fig. 2. Effect of 1 jxM bradykinin (BK) in the medium containing 1 mM glucose (G) on insulin 
secretion from the perfused rat pancreas. BK was administrated for 30 min (bar). Values are 
shown as means ± SE. The baseline concentrations of insulin in the effluents were 6.0 ± 0.5 
ng/mi (n = 4 rats) and 5.5 ± 0.6 ng/ml (n = 4 rats) for 1 mM glucose alone and bradykinin + 
glucose groups, respectively. 
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Fig. 3. Effect of 1 p.M bradykinin (BK) in the medium containing 10 mM glucose (G) on insulin 
secretion fi-om the perfused rat pancreas. BK was administrated for 30 min (bar). Values are 
shown as means ± SE. The baseline concentrations of insulin in the effluents were 6.5 ± 0.6 (n = 
6 rats) and 6.8 ± 0.5 ng/ml (n = 6 rats) for 10 mM glucose alone and bradykinin + glucose 
groups, respectively. 
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Fig. 4. Effect of 1 fxM bradykinin (BK) in the medium containing 20 mM glucose (G) on insulin 
secretion fi-om the perfused rat pancreas. BK was administrated for 30 min (bar). Values are 
shown as means ± SE. The baseline concentrations of insulin in the effluents were 5.5 ± 0.5 (n = 
4 rats) and 5.8 ± 0.5 ng/ml (n = 4 rats) for 20 mM glucose alone and bradykinin + glucose 
groups, respectively. 
66 
By calculating the areas under the 30 minutes insulin secretion curve and by using the area 
of 6 mM glucose treatment group as 100%, glucose induced a dose-dependent increase in insulin 
secretion, and BK significantly potentiated glucose-induced insulin secretion in a glucose-dose-
dependent manner (Fig. 5). The higher the glucose concentration, the more potentiation. 
Discussion 
The major kinin released in rats is BK (Bhoola et al., 1992). The BK concentration of rat 
pancreas is not known; however, the kininogen precursors are abundant in plasma (55 ng/ml) 
(Bhoola et al., 1992; Reddigari and Kaplan, 1989) and the circulatory kininogens can bind to the 
surface receptors of the endothelial cells as a substrate for BK synthesis (Schmaier et al., 1987). 
In addition, the catalytic enzymes, kallikreins are synthesized and rich in the pancreas (Bhoola et 
al., 1992; Pinkus et al., 1983). The concentration of BK are in the range of ng/mg protein or |iM 
in the rat submaxillary gland (Scicli et al., 1983) and kidney (Barabe et a!., 1988). 
BK decreases blood glucose concentration in patients with non-insulin dependent diabetic 
mellitus (Wicklmayr and Dietze, 1977), and regulates the availability and utilization of glucose in 
the target tissues (Jauch et al., 1989). In our previous report, we perfused rat pancreata with BK 
which dose-dependently increased insulin release through activation of Bl^-receptors (Yang and 
Hsu, 1995). In the present study, BK potentiated glucose-induced insulin release in a glucose 
dose-dependent manner. Thus, the hypoglycemic effect of BK may be partly mediated through 
increased insulin release which, in turn, promotes the transport and utilization of glucose. 
We also investigated the influence of ultralow glucose of 1 mM (18 mg/dl) on insulin 
release from the perfused rat pancreas. The abnormally low glucose concentration of 1 mM alone 
significantly decreased the basal insulin release to a level of 30-40% of the baseline level. 
Glucose of 6 mM (108 mg/dl) which is close to normal physiological concentration, maintained a 
steady insulin secretion throughout the perfusion period, whereas, glucose at high concentration of 
10 and 20 mM induced a biphasic insulin secretion pattern, characterized by a transient peak and a 
sustained phase. These results were similar to those found in isolated perfused rat pancreata 
(Grodsky and Bennett, 1963; Grodsky et al., 1969) and in humans (Cerasi, 1967; Cerasi and Luft, 
1967). The transient phase is attribute to the rapid transport and release of pre-existing insulin 
from the secretory granules, whereas, the sustained phase is attributed to both the increased 
synthesis of insulin and the release of stored insulin (Lacy, 1970; Lacy et al., 1972). 
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Perfusion of rat pancreata with BK for 5 min induced only a transient release of insulin 
(Yang and Hsu, 1995). Thus, in a short-term administration, BK may only stimulate insulin 
release. However, in the present study, administration of BK for 30 min induced a biphasic 
insulin secretion. Thus, in the long-term administration of 30 min, BK not only stimulates insulin 
release, but also increases both the synthesis and the release of insulin. 
BK in the presence of 1 mM glucose only had a small and transient stimulating effect on 
insulin secretion, whereas it induced a greater increase in insulin secretion in high glucose 
concentrations than that in low glucose concentrations in both phases. Therefore, we suggest that 
BK induces insulin secretion in a glucose-dependent manner. Glucose dependency also occurs to 
glucagon-like peptides-1-induced insulin secretion (Hargrove et al., 1995; Goke et al., 1993). In 
normal rats, GLP-1 (5 pmol/min/kg IV) only induces a small transient increase in plasma insulin 
in vivo, whereas, at high glucose concentrations of 11 and 17 mM, it induces an incremental 
increase in insulin (Hargrove et al., 1995). The glucose dependency of cholecystokinin-8-induced 
insulin secretion also occurs at the high glucose levels of 11.1 and 16.7 mM in rat perfused 
pancreata and perifused islets (Kimura et al., 1994). These reports were similar to our findings. 
However, in isolated rat islet, the onset of GLP-1 (25 nM)-induced insulin secretion was at 3 mM 
glucose, whereas, in perfused pancreas, it induces a strong insulin secretion at 5 mM glucose 
(Goke et al., 1993). 
In our previous study, BK enhances 10 mM glucose-induced insulin release (Yang and 
Hsu, 1995). In addition, the specific BKj-receptor antagonist, HOE 140 (0.1 ^M), reduces the 
basal and glucose-induced insulin secretion (Yang and Hsu, 1995). Thus, endogenous BK may be 
involved in glucose-induced insulin secretion under normal physiological conditions. In the 
present study (Fig. 5), when BK was administered in the presence of glucose concentrations from 
1, 6, 10 and 20 mM for 30 min, the potentiation by BK of insulin secretion was increased as the 
concentration of glucose increased. With high glucose concentration (10 or 20 mM), BK also 
induced a higher sustained insulin secretion phase than the transient insulin release peak. Further 
studies are needed to determine the concentration of BK in the pancreas and the mechanisms by 
which BK potentiates glucose-induced insulin secretion. 
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CHAPTER 4. THE EFFECT OF BRADYKBVIN ON THE SECRETION 
OF INSULIN, GLUCAGON AND SOMATOSTATIN 
FROM THE PERFUSED RAT PANCREAS 
A paper to be submitted to the American Journal of Physiology 
Chi Yang and Walter H. Hsu 
Abstract 
In order to evaluate the effect of bradykinin (BK) on rat islet a-cells, 3 cells and 5-cells, 
rat pancreata were perfused in situ with BK (1 (xM) for 30 min via a cannula placed in the celiac 
artery. We measured insulin, glucagon and somatostatin concentrations in the effluents to 
determine the effect of BK on the secretion of these hormones. The basal secretion of insulin, 
glucagon and somatostatin in the medium containing 6 mM glucose was maintained at 6.5 ± 0.5 
ng/ml (n =12), 124 ± 8 pg/ml (n =8) and 511 + 22 pg/ml (n = 12), respectively. BK (1 ^M) 
induced a biphasic insulin secretion which was characterized by a transient peak which was 3.7-
fold of the baseline concentration at < 3 min and a sustained phase. BK also transiently increased 
glucagon secretion with a peak which was 1.7-fold of the baseline concentration at < 3 min , 
without a sustained secretion phase. BK also caused a reduction in somatostatin secretion within 3 
min to a level of 60-70 % of the baseline concentration. We concluded that BK stimulated a 
biphasic insulin secretion response, transiently increased glucagon secretion and decreased 
somatostatin secretion during the 30 min perfusion of the rat pancreas. 
Introduction 
Kinins, including bradykinin (BK), display an extraordinarily high degree of physiological 
activities. They influence a number of biological processes, including blood pressure and local 
blood flow (Pan et al., 1993), pain (Steranka et al., 1988) and inflammation (Figueroa,1990), 
increased vascular permeability and local edema (Carter et al., 1974), contraction of smooth 
muscle (Collier et al., 1962), decreased blood glucose concentration, (Wicklmayr and Dietze, 
1977), promotion of cell proliferation (Goldstein et al., 1984), increased glucose uptake by intact 
intestine (Sharp and Debnam, 1992), and other cellular functions. 
lA 
Kinins also stimulate the secretion of other hormones, such as renin from isolated rat 
glomeruli (Beierwaltes et al., 1985), vasopressin from rat posterior pituitary gland (Baertschi et al., 
1981), prolactin and growth hormone from rat anterior pituitary gland (Drouhault et al., 1987) , 
catecholamines from vas deferens nerve terminals (Liona et al., 1991). At least two BK-receptor 
have been characterized, BK, and BKj, but most of the effects of BK are mediated through BKj-
receptors (Roberts, 1989). 
In our previous study, administration of BK for 5 min dose-dependently stimulated insulin 
secretion from the perfused rat pancreas and this was mediated by BKj-receptors. The BKj-
receptors blocker, HOE 140, reduced the basal insulin secretion, abolished the BK-induced insulin 
release, and attenuated the glucose-stimulated insulin release. BK also increased glucose (10 mM)-
induced insulin release (Yang and Hsu, 1995). Our fmdings suggest that, BK may be 
physiologically involved in maintaining the basal and glucose-induced insulin secretion. However, 
in addition to insulin-secreting cells (P cells), islets also have glucagon-secreting cells (a cells), 
somatostatin-secreting cells (S cells), and other types of cells for controlling glucose homeostasis 
(Hazelwood, 1989). The effects of BK on these types of cells are still not understood. Thus, the 
present study was undertaken to investigate the effect of BK on insulin, glucagon and somatostatin 
secretion. 
Materials and Methods 
Male Sprague-Dawley rats (300-400 g) were anesthetized with pentobarbital sodium (60 
mg/kg ip; Fort Dodge Labs, Fort Dodge, LA) and kept on a 37°C hot plate. The rat pancreatic 
perfusion was performed as previously described (Yang and Hsu, 1995). After celiac arteries were 
cannulated, the rat pancreata were immediately perfused in situ with oxygenated (95% ©2/5% CO2) 
Krebs-Ringer bicarbonate (KRB) solution supplemented with 10 mM N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid (HEPES), 6 mM glucose, 0.2% bovine serum albumin and pH 7.4 as 
basal medium. The perfusion rate was maintained at 1 ml/min and the effluent was collected from 
a cannula placed in the portal vein. 
After the rat pancreatic preparations were established, the first 10-15 min of perfusion was 
considered as an equilibration period. Subsequently, the effluent fluid was collected each min for 
10 min as baseline insulin secretion and the rat pancreata were continuously perfused with BK (1 
|j.M) (Sigma Chemicals, St. Louis, MO) for 30 min followed by a 5 min perfusion with the basal 
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medium. In our previous study, BK (0.01 - 1 nM) dose-dependently increases insulin release and 
BK 1 |i.M induces a about 3.7-fold increase of the baseline level (Yang and Hsu, 1995). 
Therefore, we used 1 jiM BK in these experiments. The rat pancreata of the control group were 
perfused with 6 mM glucose in KRB medium only. 
The effluents were centrifuged (lOOOx g), then 0.5 ml of the effluents was mixed with 1 
ml acid-ethanol (95% of 95% ethanol and 5% of 1 N HCl). The mixtures were centrifuged 
(lOOOx g) again and the supematants were collected, stored at -20°C for measuring the 
concentrations of glucagon and somatostatin by using radioimmunoassay (RIA). An aliquot of the 
effluent was kept at 4°C and subsequently assayed within 12 h for insulin by using RIA as 
previously described (Hale and Randle, 1963). The glucagon RIA kit was purchased from Linco 
Research, INC. St. Charles, MO and the measurement of glucagon was determined according to 
the instructions of the manufacturer. Somatostatin was measured by an RIA as previously 
described (Patel and Reichlin, 1978). 
Values are shown as means ± SE. Data were analyzed by using analysis of variance 
(ANOVA) to determine the significance of treatment and time. The treatment x time interaction 
was used as an error term to determine the effect of treatment. The significance of treatment was 
determined from the conservative F value. Tukey's highly significant different test was used to 
determine the differences between treatments for which the ANOVA indicated a significant (P < 
0.05) F ratio. 
Results 
The rat pancreata in the control group were only perfused with 6 mM glucose, and the 
baseline insulin concentrations were 6.7 ± 0.5 ng/ml throughout the perfusion period. BK (1 |J.M) 
induced a biphasic insulin release pattern (Fig. 1). The onset time of insulin release was less than 
1 min and reached a peak which was 270 % over the baseline concentration at < 3 min; then the 
insulin concentrations decreased gradually within 5 min to a sustained level which was still 
significantly higher (-50 %) than that of the control group throughout the perfiision period. The 
combination of BK and 6 mM glucose in insulin secretion was significantly higher than that of 6 
mM glucose alone. 
The concentrations of glucagon in the control group were maintained at a steady level 
which was ~ 128 ± 8 pg/ml throughout the perfusion period. Due to the increased variance, there 
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Fig. 1. Effect of 1 fiM bradykinin (BK) in the medium containing 6 mM glucose on the secretion 
of insulin, glucagon and somatostatin from the perfused rat pancreas. BK was administrated for 
30 min (bar). Values are shown as means ± SE. There was an equilibration period of 10 to 15 
min in which basal medium containing 6 mM glucose was perfused before time 0. The baseline 
concentrations of insulin, glucagon and somatostatin in the effluents were 6.7 ± 0.5 ng/ml (n = 4 
rats) and 6.6 ± 0.5 ng/ml (n = 8 rats), 128 ± 8 pg/ml (n = 4 rats) and 119 + 7 pg/ml (n = 4 rats), 
522 ± 25 pg/ml (n = 4 rats) and 505 + 20 pg/ml (n = 8 rats) for control and bradykinin + glucose 
groups, respectively. 
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was no significance difference between the treatments in the 30 min perfusion period. However, 
BK (1 |j,M) transiently and significantly increased glucagon secretion which reached a peak within 
3 min, and was ~70 % greater than the baseline concentration; the concentrations of glucagon of the 
effluent decreased to the baseline concentration within 3 min (Fig. 1). 
The somatostatin concentrations of the effluent in the control group were maintained at 
522 + 25 pg/ml throughout the perfusion period. Administration of BK (1 pM) significantly 
decreased somatostatin concentrations in the effluents to ~ 60 % of the baseline concentration 
within 3 min and maintained steadily at this level to the end of the perfusion (Fig. 1). 
Discussion 
Although, the physiological concentration of BK in the pancreas is not known, the 
precursors, kininogens are abundant in plasma (55 |ig/ml) (Bhoola et al., 1992; Reddigari and 
Kaplan, 1989) and the circulatory kininogens bind to the surface receptors of the endothelial cells 
as a substrate for BK synthesis (Schmaier et al., 1987). The catalytic enzymes, kallikreins are 
synthesized and rich in the pancreas (Bhoola et al., 1992; Pinkus et al., 1983). In addition, the 
concentrations of BK are detected in the range of ng/mg protein or |j,M in the rat submaxillary 
gland (Scicli et al., 1983) and kidney (Barabe et al., 1988). 
Glucose, at higher concentrations of > 10 mM, induces a biphasic insulin secretion which 
was characterized by a transient insulin release followed by a sustained insulin secretion phase in 
isolated perfused rat pancreas (Grodsky et al., 1969) and in humans (Cerasi and Luft, 1967). 
However, the present results showed that glucose of 6 mM, similar to normal physiological 
concentration, only maintained a steady insulin secretion at 6.5 ± 0.5 ng/ml (n =12). 
BK (1 }j,M) induced a biphasic insulin secretion and transiently increased glucagon 
secretion, but decreased the secretion of somatostatin during the 30 min period of the pancreatic 
perfusion. The initial transient insulin release was similar to our previous study in which rat 
pancreata were perfused with BK only for 5 min (Yang and Hsu, 1995). BK also induced a 
second plateau phase of insulin secretion in this 30 min perfusion. 
Intra-islet communication among a, (3 and 5 cells may occur through paracrine (interstitial) 
and/or vascular routes. The microvascular circulating cellular order, from P cells to a cells and 
from a cells to 5 cells, also influences the secretion of islet hormones (Stagner et al., 1988). Thus 
insulin regulates the secretion of glucagon, and both insulin and glucagon regulate the secretion of 
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somatostatin (Samols and Stagner, 1990). The intra-islet insulin promotes the transport of glucose 
entering a cells and inhibits the secretion of glucagon (Greenbaum et al., 1991). In addition, the 
amount of released insulin during the early period of stimulation determines the rapidity and 
magnitude of inhibition to the secretory fiinction of a cells (Leclercq-meyer et al., 1983). In the 
present study, BK stimulated a cells and transiently increased glucagon release, and the BK-
induced increase in insulin secretion inhibited glucagon secretion, thus the glucagon concentrations 
returned to the baseline levels. 
In isolated perfused rat pancreas, glucose stimulates the secretion of insulin and 
somatostatin. The released somatostatin concentration is insufficient to inhibit glucose-induced 
insulin secretion (Sorenson et al., 1980). However, exogenous insulin suppressed glucose- and 
arginine-induced somatostatin secretion (Gerber et al., 1981). In our studies, the reduction in the 
somatostatin secretion may have been caused by a direct action of BK or BK-induced insulin 
release. At present, the mechanisms of action of BK on the secretion of glucagon and 
somatostatin are unknovra. Glucagon- and somatostatin-secreting cell lines are needed to explore 
the direct action of BK on the secretion of these hormone secretion and to investigate the 
mechanisms of action of BK. 
In the cellular order of microvascular circulation, 5 cells are last and thus 5 cells are not a 
paracrine regulator of islet hormone secretion, but may be important in the regulation of exocrine 
function (Samols and Stagner, 1990). The periacinal islet hormones are high (Bendayan, 1993) 
and islet hormone (insulin and somatostatin) receptors exist on the plasma membrane of pancreatic 
acinar cells (Bendayan, 1990). The released insulin directly regulates the release of zymogen, 
glucose transport, and protein synthesis (Williams and Goldfine, 1985) and increases secretin-
induced pancreatic juice release, but not the release of protein, whereas both glucagon and 
somatostatin inhibit secretin-induced pancreatic juice and protein secretion (Hasegawa et al., 1993). 
Therefore, BK may play a physiological role in the control of the function of exocrine pancreas 
via its effects on endocrine pancreas. 
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CHAPTER 5. MECHANISMS OF BRADYKBVIN-INDUCED 
INSULIN SECRETION AND A RISE IN CYTOSOLIC 
Ca'^ IN A CLONAL p-CELL LINE RINmSF 
A paper that has been submitted to the American Journal of Physiology 
Chi Yang, Bumsup Lee, Ter-Hsin Chen and Walter H. Hsu 
Abstract 
The present study investigated the mechanisms underlying the bradykinin (BK)-induced 
rise in [Ca^^, and insulin secretion using a clonal P-cell line RINmSF. BK concentration-
dependently increased insulin secretion from 10 nM to 10 [xM and [Ca^^j from 100 nM to 100 
|iM. In Ca^'^-containing medium, BK (1 fiM) induced a diphasic [Ca^'^j rise which was 
characterized by a Ca^"^ spike and a sustained Ca^"^ phase. In the Ca^^-free medium, BK failed to 
increase insulin secretion and induced only a Ca^^ spike without the sustained Ca^^ phase. 
Thapsigargin (TG) (1 nM), an inhibitor of the Ca^'^pump in the endoplasmic reticulum (ER), 
abolished both the Ca^^ spike and the sustained phase. Nimodipine (1 nM), a voltage-dependent 
Ca^^ channel blocker, abolished the BK-induced sustained Ca^"^ phase and inhibited BK-induced 
insulin release. The BK,-receptor agonist desArg'-BK (1 fiM) did not change [Ca^"], or insulin 
secretion. Both BK-induced insulin secretion and a rise in [Ca^^j were dose-dependently inhibited 
by a selective BKj-receptor antagonist HOE140 (3.3 to 100 nM), but were not inhibited by a BK,-
receptor antagonist desArg',leu'-BK (I ^M). Pertussis toxin (PTX) (0.1 ng/ml) did not block the 
BK-induced insulin secretion or an increase in [Ca^^j. U-73122 (4, 6 and 8 nM), a phospholipase 
C (PLC) inhibitor, dose-dependently inhibited both BK-induced insulin secretion and an increase 
in [Ca^^]i in a parallel manner. BK increased intracellular concentrations of IP3, but did not 
increase cAMP formation. Ro 31-8220 (3 and 10 |iM), a PKC inhibitor, dose-dependently 
increased BK-induced insulin secretion and an increase in [Ca^^;, whereas, GAG, an analogue of 
diacylglycerol (DAG), dose-dependently inhibited the BK-induced insulin secretion and the 
increase in [Ca^^;. Ro 31-8220 increased the BK-induced Ca^^ spike and the sustained Ca^^ phase. 
OAG (30 nM) inhibited the BK-induced sustained Ca^^ phase. In Ca^'^-free medium, Ro 31-8220 
and OAG did not alter the BK-induced increase in Nimodipine abolished BK-induced Ca^^ 
influx, but did not abolish the BK-induced Ca^^ influx in Ro 31-8220 pretreated cells. ACA (100 
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HM), a PLA2 inhibitor, or L- NAME (100 |iM), a nitric oxide synthase inhibitor, did not inhibit 
these effects of BK. Taken together, these findings suggested that in fj-celis, BK activates the 
BK,-receptor which, in turn, activates PTX-insensitive G protein, probably G,. The G protein 
activates PLC which promotes the formation of inositol, 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). IP3 releases [Ca^^li froni the intracellular Ca^"" stores, probably the ER, 
which triggers Cir* influx via voltage-dependent channels and thus increases insulin secretion. 
DAG activates protein kinase C (PKC) which, in turn, brings [Ca'^j back to normal by promoting 
Ca""^ efflux and inhibiting Ca^"" influx. 
Introduction 
The autacoid bradykinin (BK) is a potent vasoactive nonapeptide. Kinins including BK 
and kallidin, an analog of BK, influence a number of biological processes. They regulate blood 
pressure and local blood flow (Pan et al., 1993), produce pain (Steranka et al., 1988) and 
inflammation (Figueroa,1990), increase vascular permeability and local edema (Carter et al., 1974), 
contract smooth muscle (Collier et al., 1962), increase cell proliferation (Marceau and Tremble, 
1986), increase glucose uptake (Sharp and Debnam, 1992) and decrease blood glucose 
concentration (Wicklmayr and Dietze, 1977), and affect other cellular functions. The effects of 
BK are mediated by at least two groups of BK receptors, BK,- and BK2. BK,-receptors mediate 
the acute inflammatory response, whereas BKj-receptors are responsible for most of the biological 
activities of kinins (Regoli et al., 1993). 
In our previous report, we demonstrated that BK stimulated insulin secretion via BK-
receptors in a dose-dependent manner from the perfused rat pancreas (Yang and Hsu, 1995). 
However, the mechanisms underlying BK-induced insulin secretion remain unknown. In general, 
kinin receptors are coupled to G proteins which may be pertussis toxin (PTX)-sensitive or -
insensitive (Bhoola et al., 1992), and at least four possible signal transduction pathways may 
mediate the effects of BK in other cellular systems: 1) phospholipase C (PLC) which hydrolyzes 
phosphatidylinositol 4,5-bisphosphate (PIP2) to form inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG); IP3 mobilizes [Ca'^, from the intracellular Ca^^ store of the endoplasmic 
reticulum (ER) (Takeuchi et al., 1988); 2) phospholipase Aj (PLAj) which increases the formation 
of arachidonic acid (Birch and Axelrod, 1987), arachidonic acid, in turn, mobilizes Ca^'^from the 
ER and opens voltage-dependent Ca^"^ channels (Konrad et al., 1992; Fernandez and Balsinde, 
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1991); 3) adenylate cyclase which increases cAMP formation (Suidan et a!., 1991); and 4) nitric 
oxide synthase (NOS) which increases the formation of nitric oxide (NO) (Mombouli and 
Vanhoutte, 1995). Therefore, in this study, we sought to determine which signal transduction 
pathways mediate the effects of BK on insulin secretion. 
We proposed that in (J-cells, the effects of BK-induced insulin secretion and an increase in 
[Ca^^i are mediated through the PLC-IP, signal transduction pathway. Therefore, we used a 
clonal insulin-secreting |3-cell line RINmSF to explore the mechanisms underlying BK-induced 
insulin secretion. 
Materials and Methods 
Cell culture 
A clonal insulin-secreting P-cell line, RINmSF, donated by Dr. S. B. Pek of the University 
of Michigan, Ann Arbor, was maintained in RPMI-1640 medium supplemented with 10% fetal 
bovine serum and aerated with 5% CO^I 95% air, as described by Thomas et al. (1989). The cells 
were cultured for 5 days and the passages from 42 to 55 were used for these experiments. 
Insulin secretion and measurement 
RINmSF cells were plated into 24-well plastic plates (Coming Glass Works, Coming, NY) 
at 2 x 10' cells/130 mm well and grown for S days. During the experiments, the culture medium 
was removed and replaced with Krebs-Ringer Bicarbonate (KRB) solution containing (in mM): 
136 NaCl, 4.8 KCl, 1.2 CaCl^, 1.2 KH2PO4, 1.2 MgS04, 5 NaHCOj, 10 HEPES, 4 glucose, 0.1% 
bovine serum albumin, pH 7.4. The cells were preincubated for 15 min at 37°C, then were 
incubated in KRB with the test agent as described by Hsu et al (1991). When needed, cells were 
pretreated with HOE140 (D-Arg[Hyp^ Thi^ D-Tic', Oic']BK), desArg',Leu®-BK, U-73122 and 
U-73343 (l-[6-[[17P-3-methoxyestra-l,3,S(10)-trien-17-yl]amino]hexyl]-lH-pyrrole-2,S-dione), 
ACA (p-amylcinnamoyi) anthranilic acid), NAME (N°-nitro-L-arginine methyl ester), or 
nimodipine for 5 min before BK administration. Cells were pretreated with Pertussis toxin (PTX) 
(0.1 fig/ml) for 16 h and Ro-31-8220 for 30 min. OAG (l-oleoyl-2-acetyl glycerol) was given 30 
sec before BK administration. The supematants were collected, kept at 4°C, and subsequently 
assayed within 12 hours for insulin by using radioimmunoassay (RIA) as described by Hsu et al. 
(1991). 
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Measurement of [Ca^*]j 
Cultured RINmSF cells of ~ 30 x 10^ cells were loaded with 2 jxM fura-2 
acetoxymethylester (AM) in KRB for 30 min at 37°C. Then the loaded cells were centrifuged 
(200 X g) and resuspended in KRB, and kept at room temperature for the [Ca^""], measurement. 
The cells were resuspended at a concentration of lOVml and 1.5-mI aliquots were used for [Ca""^]; 
measurement at room temperature (24°C). In the absence of extracellular Ca^^, cells were 
centrifuged (200 x g) and were resuspended in Ca^^-free/EGTA (10 ^M) medium. The 340 
nm/380 nm fluorescence ratios were monitored in a SLM-8000 fluorescence spectrophotometer 
(SLM, Urbana, IL). [Ca^"]i was calibrated after cell lysis as described by Hsu et al. (1991). When 
needed, cells were pretreated with HOE140, desArg',Leu'-BK, U-73122, ACA, NAME, 
nimodipine for 100-sec before BK administration. Cells were pretreated with PTX (0.1 (ig/ml) for 
2 hour, thapsigargin and Ro 31-8220 for 30 min before [Ca^^; measurement. OAG was given 30 
sec before BK administration. 
Measurement of IPj (inositol l,4,S-trisphospiiate) 
Intracellular IP3 concentration was measured using a radioreceptor-binding assay kit 
purchased from DuPont Co., Boston, MA. 1.5 x 10® cells in 1 ml KRB were placed in 
polypropylene tubes and the treatment with BK was terminated in 10 sec by adding 20% (w/v) of 
ice-cold trichloroacetic acid. The concentration of IP3 was determined according to instructions of 
the manufacturer. 
Cyclic AMP measurement 
Cyclic AMP concentrations in cultured cell monolayers were studied under conditions similar to 
the insulin secretion experiments and were determined by using RIA as previously described 
(Richards et al., 1979). 
Data expression and statistical analysis. 
Data are expressed as means ± SB . Results were analyzed using the Student's t test for 
paired and unpaired values. The significant level was set at P < 0.05. 
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Materials 
All chemicals were from Sigma Chemical Co. (St. Louis, MO), except that HOE 140 was 
donated by Hoechst-Roussel Pharmaceuticals (Somerville, NJ); U-73122, U-73343 and ACA were 
from Biomol Research Laboratory (Plymouth Meeting, PA); nimodipine was from Research 
Biochemicals International (Natick, MA); Ro-31-8220 was donated by Roche product 
(Herfordshire, UK); fura-2 AM was from Molecular Probes (Eugene, OR). 
Results 
Effects of BK on Insulin Secretion and [Ca^^], Increase 
BK (10 nM to 10 |aM) dose-dependently increased insulin secretion (Fig. lA). BK (1 nM) 
significantly increased insulin secretion which was 3.8 times of the basal control level. The 
insulin concentrations of basal control group were 0.35 + 0.02 ng/well/ml (n = 12). BK (I |4.M) 
failed to induce insulin secretion in Ca^'^-free medium (control = 0.34 ± 0.02 tig/well/min; BK -
0.35 ± O.OI ng/well/min, n = 4, P> 0.05). 
BK (100 nM to 100 jaM) increased [Ca^^]j in a dose-dependent manner (Fig. IB). BK (1 
fxM) significantly increased [Ca^"^]; which was 98 % (at the peak) over the baseline level. The 
[Ca^"^]; of baseline was 120 ± 5 nM (n = 4) (Fig. IB). In Ca^^-containing medium, BK (1 }iM) 
induced a transient Ca^^ spike which reached a peak (238 ± 6 nM, n = 8) at ~ 20 sec and this 
followed by a sustained Ca^^ plateau phase which gradually declined to the baseline level over 4 
min (Fig. 2). In the Ca^^-free medium, BK (1 |xM) only induced a transient Ca^^ spike (168 ± 5 
nM, n = 8) without the sustained Ca^"^ phase (Fig. 2). The baseline [Ca^^j in Ca^'^-free/EGTA 
medium was 88 ± 4 nM (n = 8) (Fig. 2). 
Effects of BK-receptor Agonists and Antagonists on Insulin Secretion and [Ca^*^]; Increase 
BK (1 |J.M) significantly induced insulin secretion (Fig. 3) and an increase in [Ca^"^]; (at the 
peak) (Fig.4), but desArg'-BK, a BK|-receptor agonist, did not induce insulin secretion (Fig. 3) or 
an increase in [Ca^^]j (Fig.4). HOE140 (1 /xM), a BKz-receptor antagonist, inhibited both the BK-
induced insulin secretion (Figs. 3 and 5A) and an increase in [Ca^"^]; (Figs. 4 and 5B). In contrast, 
desArg®, leu'-BK (1 |J.M), a BK,-receptor antagonist, failed to alter this effect of BK (Fig. 3 and 
4). HOE140 (3 - 100 nM) dose-dependently inhibited both the BK-induced insulin secretion (Fig. 
5A) and [Ca^^]; increases (Fig. SB). HOE 140 at 100 nM abolished the BK-induced insulin 
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Fig. 1. Effects of bradykinin (BK) on insulin secretion (A) and peak [Ca^^]j increase (B) in 
RINmSF cells. In this and the following figures, static incubation for 15 min was performed to 
measure insulin secretion. *p < 0.05, compared with the insulin concentration of basal control 
group which was 0.35 ± 0.02 ng/well/min (n = 12, A) or with the baseline level of [Ca^'"]; which 
was 120 + 5 nM (n = 24, B). 
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Fig. 2. Effects of bradykinin (BK) on the increase of [Ca^"^]; in the Ca^'^-containing (a) or Ca^*-
free (b) medium. BK (1 (xM) was administered at 1 min. Data shown are representative of eight 
experiments. Fura-2-loaded RINmSF cells were suspended in 1.5 mM of Ca~'^ or Ca"*-free 
medium. 
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Fig. 3. Effects of bradykinin (BK) and desArg-BK on insulin secretion, and desArg,Leu-BK and 
HOE140 on BK-induced insulin secretion in RINmSF cells. desArg,Leu-BK or HOE140 was 
given 5 min before BK administration. *p < 0.05, compared with the insulin concentration of the 
basal control group. 
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Fig. 4. Effects of bradykinin (BK) and desArg-BK on peak [Ca^^Jj increase, and desArg,Leu-BK 
and HOE140 on BK-induced peak [Ca^"^]; increase in RINmSF cells. desArg,Leu-BK or HOE140 
was given 100 sec before BK administration. *p < 0.05, compared with the control group. 
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Fig. 5. Effects of HOE 140 on bradykinin (BK)-induced insulin secretion (A) and peak [Ca^*]; 
increase (B) in RINmSF cells. HOE140 was given 5 min and 100 sec before BK administration in 
insulin secretion and measurement, respectively. *p < 0.05, compared with BK (1 fiM) 
control group. The concentrations of BK-induced insulin secretion were 1.35 ± 0.03 ng/well/ml (n 
= 6, A) and BK-induced peak [Ca**]; were 235 ± 7 nM (n = 6, B). 
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secretion (Fig. 5A) and [Ca^^; increases (Fig. 5B). 
Effects of PTX and U-73122 on BK-Induced Insulin Secretion and [Ca^^^lj Increase 
Pretreatment with PTX (0.1 ng/ml) for 16 and 2 h, failed to inhibit either BK (1 (iM)-
induced insulin secretion (BK = 1.31 ± 0.04 ng/well/min; PTX + BK = 1.26 + 0.05 ng/well/min, n 
= 8; p> 0.05) or an increase in [Ca^^Jj (BK = 212 ± 5 nM; PTX + BK = 210 ± 4 nM, n = 6; 
P>0.05), respectively. PTX (0.1 fig/ml) alone did not induce insulin secretion (control = 0.35 ± 
0.03 ng/well/min; PTX = 0.36 ± 0.02 ng/well/min, n = 8; P > 0.05) or an increase in [Ca^^j 
(control = 110 ± 5 nM; PTX = 112 ± 3 nM, n = 6; ? > 0.05). U-73122 (4, 6 and 8 ^M), a PLC 
inhibitor, dose-dependently inhibited both BK-induced insulin secretion (Fig. 6A) and [Ca^""]; 
increases (Fig. 6B). U-73122 at 8 p.M prevented the BK-induced insulin secretion and [Ca^"^]; 
increase by ~ 80%, but the analog, U-73343 (8 ^.M), failed to alter the BK-induced [Ca^^Jj 
increases (data not shown). U-73122 alone significantly increased [Ca^^]; which were 8.6 ± 1 and 
11.4 ± 2 over the baseline after administered with U-73122 at the dosages of 6 and 8 jaM, 
respectively (n = 8 for each dosage level). After 100 sec, [Ca^"^]; were decreased close to baseline 
level. The baseline [Ca^^j was 123 ±1.8 nM (n = 32). 
EfTect of BK on Intracellular IP3 and Cyclic AMP Concentrations 
The basal level of IP3 was 54 ± 2.5 pmol/1.5 million cells. BK significantly increased 
intracellular IP3 concentrations by ~ 50 % over the control level within 10 s of administration (Fig. 
7). BK failed to increase intracellular cAMP concentration (data not shown). 
Effects of Thapsigargin (TG) and Nimodipine on BK-Induced Insulin Secretion and [Ca^^]; 
increase 
Pretreatment of RINm5F cells with TG (1 |jiM), a selective inhibitor of Ca^^ pump in the 
ER, for 30 min abolished the BK-induced transient Ca^^ release phase and the sustained Ca^^ 
influx phase (Fig. 8A). TG (1 |liM) alone significantly increased [Ca^"^]; with an onset of 5 sec and 
reached a peak which was 118 ± 9 nM (n = 6) over the baseline. The baseline [Ca^^]; was 122 ± 
3 nM (n = 6). Pretreatment of RINm5F cells with nimodipine (1 nM) for 5 min and 100 sec also 
dose-dependently inhibited BK-induced insulin release (Fig. 9) and abolished Ca^"^ influx (Fig. 8B), 
respectively. Nimodipine (1 |J.M) alone did not change insulin secretion (control = 0.35 ± 0.02 
ng/well/min; nimodipine = 0.39 ± 0.04 ng/well/min, n = 8; P > 0.05) or an increase in [Ca^^]; 
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Fig. 6. Effect of U-73122 on bradykinin (BK)-induced insulin secretion (A) and peak [Ca^""]; 
increase (B) in RINmSF cells. U-73122 was given 5 min and 100 sec before BK administration in 
insulin secretion and [Ca^""], measurement, respectively. *p < 0.05, compared with the BK (1 jiM) 
control group. The concentrations of BK -induced insulin secretion were 1.40 ± 0.05 ng/well/ml 
(n=8. A) and BK-induced peak [Ca^^], were 95 ± 3 nM (n=8, B). 
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Fig. 7. Effect of bradykinin (BK) on intracellular IP3 concentration in RINmSF cells. *p < 0.05, 
compared with the control group which was 54 ± 2.5 pmol/1.5 million cells (n=4). 
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Fig. 8. Effects of thapsigargin (TG) (A) and nimodipine (B) on BK-induced [Ca^"]; rise in 
RINmSF cells. A: curve a shows data of BK (1 |iM) alone as control; curve b shows the effects 
of pretreatment with TG for 30 min before BK administration. B; curve a shows data of BK (1 
|j.M) alone as control; curve b shows the effects of pretreatment with nimodipine for 100 sec 
before BK administration. Data shown are representative of six experiments 
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Fig. 9. Effects of nimodipine (NIM) on bradykinin (BK)-induced insulin secretion in RINmSF 
cells. Nimodipine was given 5 min before BK administration. *p < 0.05, compared with BK (1 
|iM) alone group. 
97 
(control = 112 ± 4 nM; nimodipine = 114 ± 2 nM, n = 6; P > 0.05). 
Effects of the Activator and Inhibitor of PKC on BK-Induced Insulin Secretion and [Ca'^'lj 
Increase 
Pretreatment of RINmSF cells with a PKC activator OAG (3 - 30 p.M) for 30 sec dose-
dependently inhibited BK-induced insulin secretion (Fig. 10). OAG (30 jxM) also abolished the 
BK-induced sustained Ca^"^ phase (Fig. 11 A). OAG (30 |J.M) alone did not increase [Ca^"^]; 
(control = 120 ± 3 nM; OAG = 119 ± 2 nM, n = 4; P > 0.05). The PKC inhibitor Ro 31-8220 
(3-10 jiM) increased BK-induced insulin secretion in a dose-dependent manner (Fig. 12). Ro 31-
8220 (10 ^iM) alone significantly increased insulin secretion which was 0.5 % over the basal 
control group (control = 0.36 ± 0.03 ng/well/min; Ro 31-8220 = 0.54 ± 0.02 ng/well/min, n = 8, jP 
< 0.05 ). Ro 31-8220 at 10 jaM further increased the BK-induced rise in [Ca^^j (Fig. IIB). Both 
the BK-induced Ca^^ spike and sustained Ca^^ phase were enhanced by the pretreatment with Ro 
31-8220 (Fig. IIB). In the Ca^^-fi-ee medium, Ro 31-8220 (10 nM) did not alter the BK-induced 
increase in [Ca^^; (BK = 75 + 4 nM; Ro 31-8220 + BK = 78.4 ± 6 nM (n = 6). Nimodipine (1 
fiM) reduced , but failed to abolish, the Ro 31-8220-enhanced BK-induced [Ca^^Jj increase (Fig. 
IIB). 
Effect of ACA and L-NAME on BK-Induced Insulin Secretion 
Neither the PLA2 inhibitor ACA (100 (xM), nor the NOS inhibitor L-NAME (100 ^M) 
affected BK (1 |j.M)-induced insulin secretion (ACA + BK = 1.24 ± 0.04 ng/well/min; L-NAME + 
BK = 1.20 ± 0.04 ng/well/min; BK = 1.27 ± 0.03 ng/well/min, n = 8; P > 0.05, compared with 
each other). 
Discussion 
The results of the present study suggested that BK increases [Ca^"^]j and insulin secretion in 
RINmSF cells by activating BKj-receptors, because BK, the nonselective BK-receptor agonist 
(Farmer 1992), induced insulin secretion and [Ca^^]; increase, but a BKj-receptor agonist, desArg'-
BK (Farmer, 1992), did not. In addition, the BK-induced insulin secretion and [Ca^^Jj increase 
were inhibited by a BK2-receptors antagonist HOE140 (Cuthbert et al., 1992), but were not altered 
by a BK,-receptor antagonist desArg',leu®-BK (Goldstein and Wall, 1984). This finding is 
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Fig. 10. Effect of l-oleoyl-2-acetyl glycerol (OAG) on bradykinin (BK)-induced insulin secretion 
in RINm5F cells. OAG was given 30 sec before BK administration. *p < 0.05, compared with 
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Fig. 11. Effect of an activator and inhibitor of PKC on BK-induced [Ca^*]; increase in RINmSF 
cells. A: effect of l-oleoyl-2-acetyl glycerol (OAG). Data shown are representative of four 
experiments. Curve a shows data of BK (1 nM) alone as control, and curve b shows those of the 
pretreatment with OAG (30 jiM) for 30 sec before BK. B: effect of Ro 31-822. Data shown are 
representative of six experiments. Curve a shows data of BK alone as control, curve b shows 
those of the pretreatment with Ro 31-8220 (10 jiM) for 30 min before BK and curve c shows 
those of the pretreatment with Ro 31-8220 (10 |a.M) for 30 min and with nimodipine (1 p.M) for 
100 sec before BK. 
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Fig. 12. Effect of Ro 31-8220 on bradykinin (BK)-induced insulin secretion in RINmSF cells. Ro 
31-8220 was given 30 min before BK administration. *p < 0.05, compared with the BK (1 jiM) 
control group. 
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consistent with that of our previous study in the perfiised rat pancreas (Yang and Hsu, 1995). 
Further studies are needed to explore the BK^-receptors of (3 cells using radioligand binding 
techniques. 
The BKj-receptor protein has seven-transmembrane spanning domains, and are coupled to 
G-proteins (Hess et al., 1994). There are PTX-sensitive G-proteins, such as G; and G^ (Hess et al., 
1994; Schmidt et al., 1991) and PTX-insensitive G-proteins, such as the G^ family (Phaneuf et al., 
1993). In bovine aortic endothelial cells, BK activates both Gj - and G^-proteins (Liao and 
Homey, 1993). We found that PTX at 0.1 fxg/ml failed to inhibit the stimulatory effects of BK in 
the present study, but it abolished the inhibitory effect of a,-adrenoceptor agonists on insulin 
secretion from RE^mSF cells (Chen and Hsu, 1994) and [Ca^^^Jj in HIT cells (Hsu et al., 1991) in 
previous studies. These results suggested that in RINmSF cells, BK^-receptors are coupled to a 
PTX-insensitive G-protein, probably G,, which mediates [Ca^^]; and insulin secretion. 
The G, -proteins are usually coupled to PLC (Hepler and Gilman, 1992). The specific 
PLC inhibitor, U-73122, inhibits PLC in a variety of cells such as human neutrophils and platelets 
(Bleasdale et al., 1990), rat hepatocytes (Galan et al., 1991), pancreatic acinar cells (Yule and 
Williams, 1992) and ^cells (Chen and Hsu, 1994). In the present study, BK-induced insulin 
secretion and [Ca^^]; increase were inhibited by U-73122 in a dose-dependent manner, but were not 
altered by the analog U-73343 which does not inhibit PLC activity (Smith et al., 1990). Thus, 
these results suggested that BK activates PLC which increases the formation of IP3. IP3, in turn, 
increases Ca^"^ release from the ER (Berridge, 1993). 
Intracellular Ca^^ is a major signal in insulin secretion. In many cell types, the stimulus-
response usually couples to the elevation of [Ca^^]j through Ca^^ release from intracellular stores 
and Ca^^ influx. Secretagogues, including hormones and neurotransmitters increase intracellular 
Ca^"^ leading to insulin secretion (Li et al., 1992; Komatsu et al., 1988). In RINmSF cells, BK 
induced a transient Ca^^ peak which was immediately followed by a sustained Ca^^ phase which 
was attributed to Ca^^ influx. The transient Ca^^ peak is partly attributed to the release of Ca^^ 
from intracellular stores, probably the ER, because in Ca^'^-free medium, BK only induced a Ca^"^ 
peak without the sustained Ca^^ phase. TG depletes the intracellular Ca^* stores by inhibiting the 
Ca^^ uptake of Ca^"^ pump (Thastrup et al., 1990). Our findings showed that TG abolished both 
the BK-induced transient Ca*"^ spike and sustained Ca""^ phase, suggesting that the BK-induced 
Ca^^'influx depends on BK-induced Ca^^ release. The BK-induced [Ca^^]; peak in the Ca^^-
containing medium was higher than that in the Ca^^'-free medium. Thus, the BK-induced Ca"^ 
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peak in Ca^'^-containing medium partly came from Ca^"^ release and partly came from influx. 
The Ca^^ influx may be predominantly attributed to the opening of receptor-operated channels 
(ROCs), and/or voltage-dependent Ca^^ channels (VDCCs) (Fasolato et al., 1994; Leis et al., 
1995). Our findings suggested that the BK-induced influx is predominantly mediated through 
the VDCCs, because the sustained Ca^"^ influx was abolished by a VDCC blocker, nimodipine. 
The results in the present study suggested that BK increases insulin secretion by activating 
the PLC-IP3 signal transduction system. In addition to IP, formation, activation of PLC also 
promotes the formation of DAG (Takeuchi et al., 1988). In HIT cells, carbachol and bombesin 
increase [Ca^^i and the formation of DAG which activates PKC in insulin-secreting cells (Regazzi 
et al., 1990), and thus increases insulin secretion. However, the role of PKC activation in 
mediating insulin secretion is still a matter of considerable debate. In many cell systems, PKC has 
inhibitory and stimulatory effects (Nishizuka, 1988). TPA (12-0-tetradecanoylphorbol 13-acetate) 
activates PKC and induces insulin secretion in HIT cells (Swope and Schonbrunn, 1988). The 
overnight pretreatment of HIT cells with TPA which depletes PKC activity decreases acetylcholine 
and glucose-stimulated insulin secretion (Hughes et al., 1990). The activation of PKC by DAG 
maintains glucose-induced sustained insulin secretion in rat islet (Ganesan et al., 1990) and in 
mouse islet induced by interleukin-1 (Eizirik et al., 1995). In addition, a PKC inhibitor 
staurosporine decreases insulin secretion (Zawalich et al., 1991). These observations suggest that 
PKC enhances insulin secretion in pancreatic islets and insulin-secreting cell lines. On the other 
hand, RINm5F cells treated with TPA, which depletes intracellular PKC, displays an enhanced 
insulin secretion in response to vasopressin and carbachol by activating PLC (Li et al., 1990). 
OAG which depolarizes membrane and increases [Ca^^]j also increases insulin secretion in PKC-
deficient cells (Li et al., 1990). In addition, activation of PKC also inhibits the coupling of 
receptors to PLC and interferes with insulin secretion (Li et al., 1990). Activation of PKC in 
RINmSF cells lowers [Ca^^, by promoting an active extrusion of [Ca^^j (Berggren et al., 1989), 
thereby reducing insulin secretion. Our findings suggested that activation of PKC reduces BK-
induced insulin secretion in RINmSF cells, because a PKC activator OAG inhibited BK-induced 
insulin secretion, whereas, a selective PKC inhibitor Ro 31-8220 (10 p.M) (Dieter and Fitzke, 
1991) increased BK-induced insulin secretion. 
Activation of PKC may stimulate the Ca^"^ pump or inhibit the Ca^^ channel of the plasma 
membrane, thereby decreasing [Ca^"^]; (Ziche et al., 1993; Arkhammar et al., 1994). Berggren and 
coworkers (1989) reported that PKC promotes the recovery of RINmSF cells from elevated [Ca^^]j 
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by increasing an active extrusion of Ca^^ to the extracellular space. Our findings suggested that 
PKC decreases BK-induced Ca^"^ influx or increases BK-induced C^* efflux, because in the Ca""^-
containing medium, OAG inhibited the BK-induced sustained Cs?* phase, whereas Ro 31-8220 (10 
fO-M) (Dieter and Fitzke, 1991) increased BK-induced sustained phase. In the Ca'^^-free/EGTA 
medium, Ro 31-8220 and OAG did not alter the BK-induced rise. Nimodipine (1 |j.M) 
inhibited BK-induced Ca^"^ influx, but did not abolish BK-induced Ca"^ influx in RJNmSF cells 
pretreated with Ro 31-8220. These results suggested that PKC may promote Ca^"^ efflux and 
inhibit Ca^"^ influx, thereby returning [Ca^"]i to normal range. Further studies are required which 
use ''^Ca^^ to determine the effect of PKC on Ca^"^ flux. 
BK stimulates the formation of NO in vascular endothelial cells by activating PTX-
insensitive G^ protein (Liao and Homey, 1993). NO may increase insulin secretion by activating 
guanylate cyclase and generating cGMP (Laychock et al., 1991; Pueyo et al., 1994). Our present 
results suggested that the NO signal transduction pathway is not involved in BK-induced insulin 
secretion in RINmSF cells, because a NOS inhibitor, L-NAME (100 ^M) failed to alter BK-
induced insulin secretion and [Ca^"^]; increase. In Swiss 3T3 fibroblasts, BK also activates the 
PLAj signal transduction pathway via PTX-insensitive G-proteins (Burch and Axolrod, 1987). 
The activated PLAj increases endogenous arachidonic acid which mobilizes from the ER and 
regulates VDCCs (Konrad et al., 1992) and thus induces insulin secretion (Band et al., 1992). 
However, our findings indicated that PLA2 is not involved in the BK-induced insulin secretion 
because the PLA2 inhibitor ACA (100 nM) failed to alter the effects of BK. In another study, 
ACA inhibited glucose-induced activation of PLC in (3-cells (Konrad et al., 1992). In cultured 
tracheal smooth muscle cells, BK activates adenylate cyclase and increases cAMP (Stevens et al., 
1994). However, in the present study, BK (1 |aM) did not alter the intracellular concentration of 
cAMP in RINmSF cells. Our resuhs further suggested that an increase in cAMP concentration is 
not involved in BK-induced insulin secretion. 
In summary, our results suggested that in P-cells, bradykinin activates BKj-receptors 
which, in turn, activates a receptor-coupled PTX-insensitive G, protein. The protein activates 
PLC which increases the formation of IP3 and DAG. IP3 releases Ca^"^ from the ER and triggers 
the Ca^"^ influx, leading to insulin secretion. DAG activates PKC which may promote Ca^^ efflux 
and inhibit Ca^"^ influx to return [Ca^""]; to normal range. 
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CHAPTER 6. GENERAL CONCLUSIONS 
General Discussion 
BK influences a number of biological activities. However, the physiological function of 
kallikrein-kinin system in the pancreas is unclear, except that tissue kallikrein may be involved in 
the formation of insulin from proinsulin (Ole-Moiyoi et al., 1979) and it is suppressed in diabetic 
patients (Uehara et al., 1988). A hypoglycemic effect caused by kallikrein-kinin system was first 
reported by Frey in 1932 (Bhoola et al., 1992). Kallikreins decrease the blood glucose 
concentration in diabetic patients with NIDDM or diabetic dogs (Bhoola et al., 1992) by releasing 
kinins from kininogens. Kinins produce a hypoglycemic effect by increasing the uptake of blood 
glucose (Jauch et al., 1986, 1988), and reducing glucose production (Jauch et al., 1988). In 
alloxan-induced diabetic rats, captopril, an inhibitor of aiigiotensin-converting enzyme and 
kininase, enhances BK-induced hypoglycemia (Jaffa et al., 1986). However, kinins do not have 
direct actions to increase glucose uptake or utilization, since they increase glucose oxidation only 
in the presence of insulin in rat adipocytes (Symington et al., 1988). The role of the kallikrein-
kinin system on insulin secretion was first reported by Vance and Bragg in 1969. Kallikrein 
increased insulin secretion, but BK alone failed to show a consistent increase in insulin secretion 
from the perfused canine pancreas (Vance and Bragg, 1969) or in isolated rat pancreatic islets 
(Schack et al., 1980). However, the stimulatory effect of BK from our preliminary data in the 
canine pancreatic perfusion and [Ca^']j measurement suggested that studies are needed to 
investigate the physiological role of kinins in the pancreas. 
The present studies were undertaken by using an in situ perfusion technique to investigate 
the stimulatory effect of BK-induced insulin secretion in the rat pancreas and by using a(3-cell 
line RINmSF to explore the mechanisms underlying the BK-induced insulin secretion. We 
perfused rat pancreata with BK, Lys-BK (kallidin) and T-kinin and they all induced a similar 
potency in insulin secretion. Because BK is the physiological kinin in rats (Bhoola et al., 1992), it 
was used to further explore the stimulatory effect of kinins on insulin secretion in the perfused rat 
pancreas and RJNmSF cells. BK dose-dependently increased insulin secretion (Yang and Hsu, 
1995), and enhanced glucose-induced insulin secretion in a glucose-dose-dependent manner from 
the perfused rat pancreas (Yang and Hsu, 1995). These effects of BK may be physiologically 
significant, since our preliminary data showed that the concentrations of BK in the pancreata were 
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in the range of 0.5 - 1.5 ng/mg or nM (assayed by Dr. Julie Chao, Medical University of South 
Carolina), which was similar to that in the rat submaxillary gland (Scicli et al., 1983) and kidney 
(Barabe et al., 1988). 
At least two types of kinin receptors, BK,- and BKj-receptors, have been characterized 
(Regoli et al., 1992; Bhoola et al., 1992). Most of the kinin action is mediated through BK-
receptors (Bhoola et al., 1992), whereas BKj-receptors seem to be absent and expressed only in the 
pathological state, e.g., inflammation (Bhoola et al., 1992). The stimulatory effect of BK on 
insulin secretion was mediated through BKj-receptors, because a selective BKj-receptor antagonist 
HOE 140 (Cuthbert et ai., 1992) abolished BK-induced insulin secretion in perfused rat pancreas. 
This effect was further confirmed by using RTNmSF cells, in which the BK-induced insulin 
secretion and an increase in [Ca^"]; were abolished by HOE140, but were not altered by a BK,-
receptor antagonist, desArg',Leu^-BK. In addition, a BRj-receptor agonist, desArg'-BK (Fanner, 
1992) failed to induce insulin secretion or an increase in [Ca^^;. Further studies are needed to 
quantify the BKj-receptors of P cells using the radioligand binding technique. 
HOE 140 also reduced glucose-induced and basal insulin secretion from the perfused rat 
pancreas (Yang and Hsu, 1995). This probably was due to a specific effect on P-cells which 
blocks the stimulatory effect of endogenous BK, since HOE140 did not inhibit basal insulin 
secretion in RINmSF cells. Thus endogenous BK and their receptors may play an important role 
in maintaining the basal and glucose-induced insulin secretion. BK also potentiated glucose-
induced insulin secretion in a glucose-dose-dependent manner. In high glucose concentrations (10 
and 20 mM), BK induced insulin secretion with a higher sustained phase than the transient peak. 
Thus BK stimulated insulin synthesis, in addition to insulin release, because the transient insulin 
release peak is due to the rapid release of pre-existing insulin from the secretory granules and the 
sustained insulin secretion phase is due to the increased synthesis and release of stored insulin in 
the perfused rat pancreas (Lacy, 1970; Lacy et al., 1972). These effects of BK may maintain 
glucose homeostasis by a rapid return of blood glucose levels to the normal range after a large 
amount of intestinal absorption of glucose. Further studies are needed to determine the 
mechanisms by which BK potentiates glucose-induced insulin secretion. 
The acinus-islet interaction on insulin secretion is not well-understood. Because the acini 
contain most of the tissue kallikrein found in the pancreas (0rstavik et al., 1981; Pinkus et al., 
1983), a reduction in acini tissue kallikrein content may decrease the formation of kinin in the 
pancreas, thereby decreasing insulin secretion. To date, we do not have direct evidence that acinar 
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tissue affects islet function, but clinical observations support this premise. Human patients with 
chronic pancreatitis or acinar atrophy develop glucose intolerance as a result of insufficient insulin 
secretion (Bendayan, 1990). This reduction in insulin secretion may be due to a lack of the islet-
acinar interaction, because the reduction in |3-cell numbers appears too small to explain the 
impaired insulin secretion. In rats with pancreatic acinar atrophy induced by a long-term Cu'i 
deficient diet (Folsch et al., 1988), both the baseline and glucose-induced insulin secretion are 
lower than the controls, but the insulin content of the islets is not significantly different between 
normal rats and rats with acinar atrophy (Folsch et al., 1988). In an unpublished study, we 
perfused the pancreas with acinar atrophy that had been induced with a Cu'^-deficient diet. The 
results from that study was inconclusive, partly because the rats receiving Cu^-deficient diet for 3 
months had lost body weight by 50% and were remarkably anemic. Thus, for further study, one 
needs to develop a method for inducing pancreatic acinar atrophy without causing severe health 
problem seen with the Cu^^-deficient diet. 
The results in the present study suggested that the effects of BK in P-cells are mediated 
through the PLC-IP3 signal transduction pathway. Because the BK-induced insulin secretion and 
[Ca^^]j increase were not altered by PTX pretreatment, the BKj-receptor was coupled to a PTX-
insensitive G-protein (G,) which is coupled to PLC (Hess et al., 1994). In addition, the effect of 
BK was inhibited by U-73122, a specific PLC inhibitor (Bleasdale et al., 1990) and BK increased 
the formation of IP3. On the other hand, our findings suggested that neither NO, cAMP, nor PLA 
signal transduction pathway is involved in BK-induced insulin secretion in P-cells, because neither 
the NOS inhibitor L-NAME nor the PLAj inhibitor ACA altered the effects of BK. BK did not 
change the intracellular concentration of cAMP in RINmSF cells. 
Intracellular Ca^"^ is a major signal in insulin secretion. The stimulus-response usually 
couples to the elevation of [Ca^"], through Ca^^ release from the intracellular store and Ca^"^ influx, 
leading to insulin secretion (Li et al., 1992; Komatsu et al., 1988). Our results showed that Ca^^ 
influx was responsible for BK-induced insulin secretion, but Ca^ release alone did not induce 
insulin secretion, because in the Ca^'^free medium, BK only induced a transient Ca^"^ release 
without the sustained Ca^^ influx and did not induce insulin secretion. In Ca^'-containing medium, 
BK induced a transient Ca^^ release and a sustained Ca^^ influx, and induced insulin secretion. 
However, the Ca^^influx depends on the Ca^"^ release, because TG, a Ca^"^ pump inhibitor (Thastrup 
et al., 1990), abolished BK-induced transient Ca^* release and sustained Ca^^ influx. Thus, in 
RINmSF cells, Ca'^ release was as important as Ca""^ influx in BK-induced insulin secretion. 
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The activation of PLC also promotes the formation of DAG. DAG activates PKC 
(Regazzi et al., 1990; Berridge., 1987). The physiological function of PKC in insulin secretion is 
still unclear. In rat islets, a-PKC at least partially mediates glucose-induced insulin secretion 
(Ganesan et al., 1990). PMA, an PKC activator, induces the translocation of PKC to a membrane-
bound state and induces insulin secretion in pancreatic islets (Easom et al., 1989), HIT cells 
(Swope and Schonbrunn, 1988) and RINmSF cells (Yada et al., 1989). HIT cells pretreated with 
PMA for 22-24 h which decreases PKC activity by 73% decreases acetylcholine- and glucose-
induced insulin secretion in HIT cells (Hughes et al., 1990). Thus, the activation of PKC 
stimulates insulin secretion (Swope and Schonbrunn, 1988; Tuch et al., 1988; Arkhammar et al., 
1986). However, glucose primarily depolarizes P-cells and promotes Ca^^ influx (Wollheim and 
Pozza, 1984). In addition, several studies have failed to demonstrate the involvement of PKC in 
glucose-induced insulin secretion (Easom et al., 1989, 1990; Regazzi et al., 1990). Although PMA 
and staurosporine have been used to study the positive effect of PKC on insulin secretion, PMA 
depolarizes plasma membrane and increases [Ca^"^],, thereby promoting insulin secretion (Yada et 
al., 1989), and at a nonstimulatory concentration of glucose (3 mM), PMA induces a slightly and 
slowly insulin secretion (Bozem et al., 1987). In the PKC-deficient rat islets, staurosporine still 
inhibits glucose-induced insulin secretion (Persaud et al., 1993). In other cell types, PMA 
activates protein kinase A (Plet et al., 1988) and PLAj (Perkins et al., 1991), and staurosporine 
inhibits not only PLC but also a variety of other protein kinases (Ruegg and Burgess, 1989). Thus 
PMA and staurosporine are not a selective activator and inhibitor of PKC, respectively. 
However, PKC may exert an inhibitory effect on insulin secretion, according to others. In 
RINmSF cells, PKC inhibits the coupling of receptors to PLC (Li et al., 1990) and promotes an 
active extrusion of [Ca^^; (Berggren et al., 1989), thereby reducing insulin secretion. PKC may 
stimulate the Ca^^ pump or inhibit the Ca^"^ channel of the plasma membrane, thereby decreasing 
[Ca^^Ji (Ziche et al., 1993; Arkhammar et al., 1994; Di-Virgilio et al., 1986). In addition, PKC-
deficient RINmSF cells display an enhanced insulin secretion in response to vasopressin and 
carbachol (Li et al., 1990). Our findings in the present study showed that PKC inhibited the effect 
of BK on insulin secretion, because GAG, an analog of DAG, decreased BK-induced insulin 
secretion and sustained Ca^^ influx, whereas, a selective PKC inhibitor Ro 31-8220 (Dieter and 
Fitzke, 1991) increased BK-induced insulin secretion and sustained Ca^^ influx. Therefore, our 
findings confirmed those of others and suggested that PKC has an inhibitory effect on insulin 
secretion in RINmSF cells. A similar inhibitory effect of PKC was found in other cell type. 
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parathyroid cells, in which PKC serves as a negative-feedback signal to damp signaling through 
the receptor-PLC pathway by phosphorylating the extracelluar Ca^-receptor and decreasing the 
ability of this receptor to increase IP3 and [Ca""];, thereby decreasing parathyroid hormone 
secretion (Nemeth, 1995). Further studies using more specific activators and inhibitors such as 
OAG and Ro 31-8220 are needed to determine the physiological significance of the inhibitory 
effect of PKC in insulin secretion. 
In summary, our results suggested that in P-cells, bradykinin activates BKj-receptors 
which, in turn, activates a receptor-coupled PTX-insensitive G-protein (C^). The G, protein 
activates PLC which increases the formation of IP, and DAG. IPj releases Ca*"^ from the ER and 
triggers the Ca^^ influx, leading to insulin secretion. DAG activates PKC which may promote 
[Ca^"^]) efflux and inhibit Ca^"^ influx to return [Ca^^j to the normal range. 
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